Cholangiocarcinoma 2020: the next horizon in mechani

Nature Reviews Gastroenterology and Hepatology
17, 557-588
DOI: 10.1038/s41575-020-0310-z

Citation Report

#	Article	IF	Citations
1	Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment. Journal of Hepatology, 2020, 73, 1007-1009.	1.8	9
2	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology, 2021, 73, 2311-2325.	3.6	40
3	Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review. Cancers, 2020, 12, 2817.	1.7	4
4	Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma. Cell Communication and Signaling, 2020, 18, 161.	2.7	4
5	Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules, 2020, 10, 1377.	1.8	5
6	In Vivo Models for Cholangiocarcinomaâ€"What Can We Learn for Human Disease?. International Journal of Molecular Sciences, 2020, 21, 4993.	1.8	8
7	Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma. European Journal of Histochemistry, 2020, 64, .	0.6	3
8	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers, 2020, 12, 3370.	1.7	28
9	A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers, 2020, 12, 3404.	1.7	17
10	Management of cholangiocarcinoma in the third millennium: time to be guided!. Digestive and Liver Disease, 2020, 52, 1428-1429.	0.4	1
11	Contrast-enhanced ultrasonography for intrahepatic cholangiocarcinoma: A cost-effective alternative for low-resource settings. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 304-305.	0.6	1
12	LncRNA TUG1 Promotes Growth and Metastasis of Cholangiocarcinoma Cells by Inhibiting miR-29a . Cancer Management and Research, 2020, Volume 12, 11103-11111.	0.9	10
13	High Prevalence of Human Polyomavirus 7 in Cholangiocarcinomas and Adjacent Peritumoral Hepatocytes: Preliminary Findings. Microorganisms, 2020, 8, 1125.	1.6	11
14	Expression of FOXO4 Inhibits Cholangiocarcinoma Cell Proliferation In Vitro via Induction of G0/G1 Arrest. Anticancer Research, 2020, 40, 6899-6905.	0.5	5
15	Novel miRNA Predicts Survival and Prognosis of Cholangiocarcinoma Based on RNA-seq Data and In Vitro Experiments. BioMed Research International, 2020, 2020, 1-14.	0.9	14
16	Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opinion on Investigational Drugs, 2021, 30, 317-324.	1.9	66
17	Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opinion on Investigational Drugs, 2021, 30, 365-375.	1.9	10
18	LGR5 induces Î²â€catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma. Liver International, 2021, 41, 865-881.	1.9	17

#	Article	IF	Citations
19	Pathogenesis of Cholangiocarcinoma. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 433-463.	9.6	63
20	Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma. Hepatology, 2021, 74, 491-502.	3.6	35
21	The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. Expert Opinion on Investigational Drugs, 2021, 30, 281-284.	1.9	7
22	Recent advances of immunotherapy for biliary tract cancer. Expert Review of Gastroenterology and Hepatology, 2021, 15, 527-536.	1.4	85
23	TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression. Journal of Hepatology, 2021, 74, 860-872.	1.8	40
24	Doublecortinâ€Like Kinase Protein 1 in Cholangiocarcinoma: Is This the Biomarker and Target We Have Been Looking For?. Hepatology, 2021, 73, 4-6.	3.6	35
25	Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Advances in Cancer Research, 2021, 149, 321-387.	1.9	18
26	Experimental HER2- targeted therapies for biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 389-399.	1.9	9
27	Nivolumab: an investigational agent for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 325-332.	1.9	7
28	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opinion on Investigational Drugs, 2021, 30, 429-438.	1.9	13
29	BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Review of Gastroenterology and Hepatology, 2021, 15, 483-485.	1.4	37
30	Long Noncoding RNAs in Cholangiocarcinoma. Hepatology, 2021, 73, 1213-1226.	3.6	11
31	The implications of treatment delays in adjuvant therapy for cholangiocarcinoma patients.. Journal of Clinical Oncology, 2021, 39, 291-291.	0.8	2
32	Risk Factors for Pancreatic Cancer and Cholangiocarcinoma. , 2021, , 3-20.		0
33	Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma. OncoImmunology, 2021, 10, 1968595.	2.1	1
34	The prognostic impact of lymphocyte-to-C-reactive protein score in patients undergoing surgical resection for intrahepatic cholangiocarcinoma: A comparative study of major representative inflammatory / immunonutritional markers. PLoS ONE, 2021, 16, e0245946.	1.1	12
35	TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks. Cancer Treatment and Research Communications, 2021, 27, 100351.	0.7	6
36	First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: â€œAnd Yet It Moves!â€• Cancer Treatment and Research Communications, 2021, 27, 100335.	0.7	55

#	Article	IF	Citations
37	Thoracoscopic metastasectomy is the method of choice in the stepwise treatment of disseminated cholangiocellular carcinoma. Onkologiya Zhurnal Imeni P A Gertsena, 2021, 10, 39.	0.0	0
38	Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma. OncoTargets and Therapy, 2021, Volume 14, 39-51.	1.0	9
39	Established and Emerging Biomarkers for Prediction, Early Detection, and Prognostication of Cholangiocarcinoma. , 2021, , 413-434.		0
40	The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treatment and Research Communications, 2021, 27, 100360.	0.7	4
41	Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treatment and Research Communications, 2021, 27, 100354.	0.7	36
42	The tireless search to improve the prognostic assessment of intrahepatic cholangiocarcinoma: An urgent need. Liver International, 2021, 41, 252-254.	1.9	3
43	Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treatment and Research Communications, 2021, 27, 100337.	0.7	57
44	Dihydromyricetin Inhibits Tumor Growth and Epithelial-Mesenchymal Transition through regulating miR-455-3p in Cholangiocarcinoma. Journal of Cancer, 2021, 12, 6058-6070.	1.2	6
45	Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. Scientific Reports, 2021, 11, 2557.	1.6	16
46	The Necessity and Method of Preoperative Drainage for Hilar Cholangiocarcinoma. Advances in Clinical Medicine, 2021, 11, 1952-1958.	0.0	0
47	Key challenges for drugs in clinical development for cholangiocarcinoma. Expert Opinion on Investigational Drugs, 2021, 30, 285-290.	1.9	5
48	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opinion on Investigational Drugs, 2021, 30, 377-388.	1.9	5
50	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opinion on Therapeutic Targets, 2021, 25, 153-162.	1.5	11
51	Extrahepatic cholangiocarcinoma: Current status of endoscopic approach and additional therapies. World Journal of Hepatology, 2021, 13, 166-186.	0.8	6
52	Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology and Hepatology, 2021, 15, 547-554.	1.4	52
53	Developing models of cholangiocarcinoma to close the translational gap in cancer research. Expert Opinion on Investigational Drugs, 2021, 30, 439-450.	1.9	3
54	Epithelialâ€“Mesenchymal Transition in Liver Fluke-Induced Cholangiocarcinoma. Cancers, 2021, 13, 791.	1.7	4
55	Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. BMC Cancer, 2021, 21, 112.	1.1	16

#	Article	IF	Citations
56	A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples. Diagnostics, 2021, 11, 610.	1.3	6
57	Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 343-350.	1.9	75
58	Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives. Expert Review of Precision Medicine and Drug Development, 2021, 6, 225-227.	0.4	12
59	Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opinion on Investigational Drugs, 2021, 30, 401-409.	1.9	10
60	Nationwide treatment and outcomes of perihilar cholangiocarcinoma. Liver International, 2021, 41, 1945-1953.	1.9	28
61	Establishment of a Potential Serum Biomarker Panel for the Diagnosis and Prognosis of Cholangiocarcinoma Using Decision Tree Algorithms. Diagnostics, 2021, 11, 589.	1.3	10
62	Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma. New England Journal of Medicine, 2021, 384, 1054-1064.	13.9	2
63	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines, 2021, 9, 422.	2.1	8
64	Cell of origin in biliary tract cancers and clinical implications. JHEP Reports, 2021, 3, 100226.	2.6	30
65	The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies. Seminars in Immunopathology, 2021, 43, 591-607.	2.8	16
66	Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. Cancers, 2021, 13, 1647.	1.7	10
67	The challenges of combinatory immunotherapy for biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 591-594.	1.9	1
68	Preoperative prediction of postsurgical outcomes in mass-forming intrahepatic cholangiocarcinoma based on clinical, radiologic, and radiomics features. European Radiology, 2021, 31, 8638-8648.	2.3	28
69	Cholangiocarcinoma: is it time for a revolution?. Expert Review of Gastroenterology and Hepatology, 2021, 15, 467-470.	1.4	1
70	Liver Mass in a Young Male With Ollier Disease. Gastroenterology, 2021, 161, e4-e5.	0.6	0
71	Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center. Cancers, 2021, 13, 2070.	1.7	6
72	Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices. Expert Review of Gastroenterology and Hepatology, 2021, 15, 487-496.	1.4	2
73	Current challenges to underpinning the genetic basis for cholangiocarcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 511-526.	1.4	3

#	Article	IF	Citations
74	The Landmark Series: Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 4158-4170.	0.7	30
75	Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?. Expert Review of Precision Medicine and Drug Development, 2021, 6, 217-224.	0.4	0
76	Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treatment Reviews, 2021, 95, 102170.	3.4	85
77	Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer. Expert Review of Gastroenterology and Hepatology, 2021, 15, 537-545.	1.4	7
78	FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic potential and poor prognosis of patients. Heliyon, 2021, 7, e06846.	1.4	7
79	Rapid recurrence of spindle cell type undifferentiated carcinoma early after radical surgery in a bile duct cancer patient â€“ A case report. International Journal of Surgery Case Reports, 2021, 81, 105800.	0.2	2
80	Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice. Cancers, 2021, 13, 2292.	1.7	6
81	Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers, 2021, 13, 2358.	1.7	9
82	Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma. Diagnostics, 2021, 11, 999.	1.3	8
83	Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World Journal of Gastrointestinal Oncology, 2021, 13, 332-350.	0.8	29
84	DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. Hepatology Communications, 2021, 5, 1448-1459.	2.0	8
85	Obesity and cholangiocarcinoma: A review of epidemiological and molecular associations. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 1047-1059.	1.4	8
86	Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma. Liver Cancer, 2021, 10, 260-274.	4.2	14
87	Radioembolization for Cholangiocarcinoma. Digestive Disease Interventions, 0, 05, .	0.3	0
88	Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2â€“Plateletâ€Derived Growth Factor Receptor Betaâ€“Yesâ€Associated Protein Signaling Axis. Hepatology, 2021, 74, 1411-1428.	3.6	10
89	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. Journal of Gastrointestinal Cancer, 2021, , 1.	0.6	0
90	Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine, 2021, 67, 103375.	2.7	33
91	Disparities in NCCNÂGuidelineÂCompliant Care for Resectable Cholangiocarcinoma at Minority-Serving Versus Non-Minority-Serving Hospitals. Annals of Surgical Oncology, 2021, 28, 8162-8171.	0.7	16

#	Article	IF	Citations
92	Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. International Journal of Molecular Sciences, 2021, 22, 5613.	1.8	9
93	Near infrared photoimmunotherapy of cancer; possible clinical applications. Nanophotonics, 2021, 10, 3135-3151.	2.9	19
94	Transcriptome and DNA methylation analysis reveals molecular mechanisms underlying intrahepatic cholangiocarcinoma progression. Journal of Cellular and Molecular Medicine, 2021, 25, 6373-6387.	1.6	5
95	Management of Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine, 2021, 10, 2368.	1.0	14
96	Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opinion on Investigational Drugs, 2021, 30, 675-679.	1.9	9
97	A Novel NIPBL-NACC1 Gene Fusion Is Characteristic of the Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma. American Journal of Surgical Pathology, 2021, 45, 1550-1560.	2.1	23
98	The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine, 2021, 10, 2428.	1.0	4
99	CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1021-1024.	1.8	2
100	A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma. BMC Cancer, 2021, 21, 608.	1.1	15
101	Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art. Expert Review of Gastroenterology and Hepatology, 2021, 15, 497-510.	1.4	10
102	Identification of Mutator-Derived Alternative Splicing Signatures of Genomic Instability for Improving the Clinical Outcome of Cholangiocarcinoma. Frontiers in Oncology, 2021, 11, 666847.	1.3	4
103	Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell, 2021, 28, 816-832.	5.2	133
104	High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection. International Journal of General Medicine, 2021, Volume 14, 2191-2204.	0.8	5
105	Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study. Scientific Reports, 2021, 11, 12166.	1.6	14
106	Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma. Cancers, 2021, 13, 2804.	1.7	22
107	Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression. Acta Pharmaceutica Sinica B, 2021, 11, 4008-4019.	5.7	17
108	Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review. Journal of Clinical Medicine, 2021, 10, 2552.	1.0	12
109	Preoperative prognostic nutritional index predicts postoperative infectious complications and oncological outcomes after hepatectomy in intrahepatic cholangiocarcinoma. BMC Cancer, 2021, 21, 708.	1.1	12

#	Article	IF	Citations
110	Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell, 2021, 39, 866-882.e11.	7.7	159
111	Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1373-1385.	1.8	60
112	Next-Generation Biomarkers for Cholangiocarcinoma. Cancers, 2021, 13, 3222.	1.7	20
113	Compelling Long-Term Results for Liver Resection in Early Cholangiocarcinoma. Journal of Clinical Medicine, 2021, 10, 2959.	1.0	7
114	Cholangiocarcinoma: Consensus statement from ENS-CCA. Annals of Hepato-biliary-pancreatic Surgery, 2021, 25, S6-S6.	0.1	0
115	New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Reports, 2021, 3, 100251.	2.6	28
116	Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologistâ€™s Role. Cancers, 2021, 13, 2871.	1.7	17
117	Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine, 2021, 10, 2803.	1.0	14
118	IGF2BP1 IS A POOR PROGNOSTIC FACTOR IN EXTRAHEPATIC CHOLANGIOCARCINOMA. , 2021, , 80-82.		0
119	Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yesâ€Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans. Hepatology, 2021, 74, 248-263.	3.6	22
120	Omega-Class Glutathione Transferases of Carcinogenic Liver Fluke, Clonorchis sinensis, Modulate Apoptosis and Differentiation of Host Cholangiocytes. Antioxidants, 2021, 10, 1017.	2.2	2
121	Clinicopathological Significance of Syndecan-1 in Cholangiocarcinoma: A Study Based on Immunohistochemistry and Public Sequencing Data. Journal of Clinical Medicine, 2021, 10, 2745.	1.0	5
122	Serum Levels of Cytokine-Induced Apoptosis Inhibitor 1 (CIAPIN1) as a Potential Prognostic Biomarker of Cholangiocarcinoma. Diagnostics, 2021, 11, 1054.	1.3	4
123	HNF-1Î² is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas. Archives of Pathology and Laboratory Medicine, 2022, 146, 220-226.	1.2	6
124	Integrated prognostication of intrahepatic cholangiocarcinoma by contrast-enhanced computed tomography: the adjunct yield of radiomics. Abdominal Radiology, 2021, 46, 4689-4700.	1.0	8
125	Cholangiocarcinoma. Pathologica, 2021, 113, 158-169.	1.3	70
126	The implications of IDH mutations for cancer development and therapy. Nature Reviews Clinical Oncology, 2021, 18, 645-661.	12.5	155
127	Novel analysis using magnetic resonance cholangiography for patients with pancreaticobiliary maljunction. Surgery Today, 2022, 52, 385-394.	0.7	1

#	Article	IF	Citations
128	Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers, 2021, 13, 3336.	1.7	19
129	The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancers, 2021, 13, 3661.	1.7	10
130	Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma. Expert Opinion on Investigational Drugs, 2021, 30, 985-1006.	1.9	3
131	Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. Oncology and Therapy, 2021, 9, 557-573.	1.0	7
132	The Role of Conventional and Stereotactic Microwave Ablation for Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine, 2021, 10, 2963.	1.0	6
133	The Emerging Role of Circ-SHPRH in Cancer. OncoTargets and Therapy, 2021, Volume 14, 4177-4188.	1.0	5
134	HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers, 2021, 13, 3862.	1.7	17
135	Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer. Cancer Discovery, 2021, 11, 3158-3177.	7.7	12
136	Impact of surgical margin width on long-term outcomes for intrahepatic cholangiocarcinoma: a multicenter study. BMC Cancer, 2021, 21, 840.	1.1	9
137	Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. Frontiers in Oncology, 2021, 11, 704042.	1.3	5
138	Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut, 2022, 71, 1141-1151.	6.1	32
139	Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?. World Journal of Gastroenterology, 2021, 27, 4252-4275.	1.4	4
140	Vascular Involvements in Cholangiocarcinoma: Tips and Tricks. Cancers, 2021, 13, 3735.	1.7	7
141	Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis. Digestive Diseases and Sciences, 2022, 67, 3284-3297.	1.1	20
142	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology, 2021, 5, 1228-1240.	1.5	2
143	The Role of microRNAs in Cholangiocarcinoma. International Journal of Molecular Sciences, 2021, 22, 7627.	1.8	18
144	Arctigenin inhibits cholangiocarcinoma progression by regulating cell migration and cell viability via the N-cadherin and apoptosis pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 2049-2059.	1.4	5
145	Current Advances in Basic and Translational Research of Cholangiocarcinoma. Cancers, 2021, 13, 3307.	1.7	5

#	Article	IF	Citations
146	A comprehensive transcriptomic landscape of cholangiocarcinoma based on bioinformatics analysis from large cohort of patients. Scientific Reports, 2021, 11, 13713.	1.6	7
147	IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Advanced Science, 2021, 8, e2101230.	5.6	26
149	Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review. Journal of Gastrointestinal Cancer, 2022, 53, 817-824.	0.6	3
150	Evaluation and Management of Malignant Biliary Obstruction. Surgical Oncology Clinics of North America, 2021, 30, 491-503.	0.6	5
151	Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 75, 1377-1386.	1.8	40
152	Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Deathâ€Ligand 1 Blockade Responses. Hepatology, 2021, 74, 1914-1931.	3.6	48
154	Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Clinical and Translational Oncology, 2022, 24, 297-304.	1.2	6
155	Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy. Frontiers in Oncology, 2021, 11, 691380.	1.3	8
156	Integration of global metabolomics and lipidomics approaches reveals the molecular mechanisms and the potential biomarkers for postoperative recurrence in early-stage cholangiocarcinoma. Cancer & Metabolism, 2021, 9, 30.	2.4	11
157	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 975-983.	1.9	7
158	GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut, 2022, 71, 1386-1398.	6.1	28
159	The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Biomedical Reports, 2021, 15, 86.	0.9	1
160	The State of Immunotherapy in Hepatobiliary Cancers. Cells, 2021, 10, 2096.	1.8	18
161	Synergistic combination of cytotoxic chemotherapy and cyclinâ€dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology, 2022, 75, 43-58.	3.6	6
162	Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. Cancers, 2021, 13, 4062.	1.7	7
163	Clinical Staging of Massâ€Forming Intrahepatic Cholangiocarcinoma: Computed Tomography Versus Magnetic Resonance Imaging. Hepatology Communications, 2021, 5, 2009-2018.	2.0	14
164	CAFs shape myeloidâ€derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5â€lipoxygenase. Hepatology, 2022, 75, 28-42.	3.6	77
165	FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. Journal of Hepatology, 2021, 75, 363-376.	1.8	29

#	Article	IF	Citations
166	Metabolic disorders and the risk of cholangiocarcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 999-1007.	1.4	9
167	Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. Hepatobiliary Surgery and Nutrition, 2021, 10, 515-517.	0.7	1
168	Diversity in cell differentiation, histology, phenotype and vasculature of massâ€forming intrahepatic cholangiocarcinomas. Histopathology, 2021, 79, 731-750.	1.6	8
169	Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities?. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1-2.	1.4	0
170	Effect of vascular resection for perihilar cholangiocarcinoma: a systematic review and meta-analysis. PeerJ, 2021, 9, e12184.	0.9	0
171	The effect of biliary obstruction, biliary drainage and bile reinfusion on bile acid metabolism and gut microbiota in mice. Liver International, 2022, 42, 135-148.	1.9	4
172	Association between the expression of core 3 synthase and survival outcomes of patients with cholangiocarcinoma. Oncology Letters, 2021, 22, 760.	0.8	3
173	Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets. Cancer Research, 2021, 81, 5765-5776.	0.4	9
174	Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World Journal of Clinical Oncology, 2021, 12, 725-745.	0.9	9
175	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. Journal of Experimental Medicine, 2021, 218, .	4.2	20
176	Evaluation of nodal status in intrahepatic cholangiocarcinoma: a population-based study. Annals of Translational Medicine, 2021, 9, 1359-1359.	0.7	10
177	Zinc Finger Eâ€Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumorâ€“Stroma Paracrine Signaling. Hepatology, 2021, 74, 3194-3212.	3.6	20
178	Mucin-producing hamster cholangiocarcinoma cell line, Ham-2, possesses the aggressive cancer phenotypes with liver and lung metastases. In Vitro Cellular and Developmental Biology - Animal, 2021, 57, 825-834.	0.7	0
179	Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Current Oncology, 2021, 28, 3393-3402.	0.9	29
180	Immunotherapy for cholangiocarcinoma: aÂ2021 update. Immunotherapy, 2021, 13, 1113-1134.	1.0	11
181	The Role of the Hedgehog Pathway in Cholangiocarcinoma. Cancers, 2021, 13, 4774.	1.7	10
182	Biliary Strictures and Cholangiocarcinoma â€“ Untangling a Diagnostic Conundrum. Frontiers in Oncology, 2021, 11, 699401.	1.3	9
183	Camrelizumab plus oxaliplatinâ€based chemotherapy as firstâ€line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. International Journal of Cancer, 2021, 149, 1944-1954.	2.3	32

#	Article	IF	Citations
184	Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma. Hepatology, 2021, 74, 3235-3248.	3.6	9
185	Advances in the management of cholangiocarcinoma. World Journal of Hepatology, 2021, 13, 1003-1018.	0.8	10
186	Toward personalized therapy for cholangiocarcinoma: new insights and challenges. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1241-1243.	1.4	2
188	Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma. Oncology Reports, 2021, 46, .	1.2	7
189	Overexpression of AGR2vH, an oncogenic AGR2 spliced transcript, potentiates tumorigenicity and proteomic alterations in cholangiocarcinoma cell. Bioscience, Biotechnology and Biochemistry, 2021, 85, 2263-2273.	0.6	2
190	The proteaseâ€inhibitor SerpinB3 as a critical modulator of the stemâ€like subset in human cholangiocarcinoma. Liver International, 2022, 42, 233-248.	1.9	15
191	Cholangiocarcinoma. Nature Reviews Disease Primers, 2021, 7, 65.	18.1	270
192	Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1267-1279.	1.4	7
193	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Digestive and Liver Disease, 2021, , .	0.4	2
194	RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach. Pharmaceuticals, 2021, 14, 898.	1.7	6
195	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. Hepatology, 2021, 74, 2622-2632.	3.6	31
196	A look back at cholangiocarcinoma in Finland. United European Gastroenterology Journal, 2021, 9, 1103-1104.	1.6	0
197	Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. Expert Opinion on Investigational Drugs, 2021, 30, 1047-1056.	1.9	4
198	Vimentin-Positive Circulating Tumor Cells as Diagnostic and Prognostic Biomarkers in Patients with Biliary Tract Cancer. Journal of Clinical Medicine, 2021, 10, 4435.	1.0	2
199	Targeting Lymphangiogenesis and Lymph Node Metastasis in Liver Cancer. American Journal of Pathology, 2021, 191, 2052-2063.	1.9	22
200	Controversial issues of biliary stenting in patients with proximal biliary obstruction. Annals of HPB Surgery, 2021, 26, 79-88.	0.1	4
201	Cholangiocarcinoma and liver transplantation: What we know so far?. World Journal of Gastrointestinal Pathophysiology, 2021, 12, 84-105.	0.5	3
202	Proposal of a New Definition of â€œVery Earlyâ€•Intrahepatic Cholangiocarcinomaâ€”A Retrospective Single-Center Analysis. Journal of Clinical Medicine, 2021, 10, 4073.	1.0	4

#	Article	IF	Citations
203	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. JAMA Oncology, 2021, 7, 1669.	3.4	194
204	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. The Lancet Gastroenterology and Hepatology, 2021, 6, 803-815.	3.7	205
205	Deciphering FAK in intrahepatic cholangiocarcinoma: A novel therapeutic target?. Journal of Hepatology, 2021, 75, 765-767.	1.8	1
206	Medical therapies for intra-hepatic cholangiocarcinoma. Journal of Hepatology, 2021, 75, 981-983.	1.8	7
207	Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases. Annals of Diagnostic Pathology, 2021, 55, 151828.	0.6	3
208	Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals, 2021, 14, 51.	1.7	7
209	Relevance of Membrane Contact Sites in Cancer Progression. Frontiers in Cell and Developmental Biology, 2020, 8, 622215.	1.8	15
210	Current and Future Systemic Therapies in Biliary Tract Cancer. Visceral Medicine, 2021, 37, 32-38.	0.5	5
211	Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer Treatment and Research Communications, 2021, 27, 100334.	0.7	9
212	Biomarkers for Pancreatic Cancer and Cholangiocarcinoma. , 2021, , 31-40.		0
213	IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110365.	1.4	24
214	One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/Î²-catenin pathways in cholangiocarcinoma. Journal of Hepatology, 2022, 76, 8-10.	1.8	5
215	Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World Journal of Gastrointestinal Oncology, 2021, 13, 1336-1366.	0.8	10
216	Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review. Journal of Clinical Medicine, 2021, 10, 4901.	1.0	7
217	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta as a potential biomarker for Opisthorchis viverrini infection and cholangiocarcinoma. Parasitology, 2022, 149, 171-180.	0.7	4
218	Epsteinâ€“Barr Virusâ€”Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies. Cancers, 2021, 13, 5189.	1.7	29
220	RNF43 overexpression attenuates the Wnt/Î²â€‘catenin signalling pathway to suppress tumour progression in cholangiocarcinoma. Oncology Letters, 2021, 22, 846.	0.8	8
221	Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Management and Research, 2021, Volume 13, 8085-8098.	0.9	9

#	Article	IF	Citations
222	FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. Life Sciences, 2021, 286, 120072.	2.0	9
223	Targeting protein kinase CK2 in the treatment of cholangiocarcinoma. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.5	1
224	Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. World Journal of Gastrointestinal Oncology, 2021, 13, 1229-1243.	0.8	9
225	Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies. Seminars in Interventional Radiology, 2021, 38, 438-444.	0.3	2
226	Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer, 2021, 21, 1079.	1.1	14
228	Novel therapeutic targets for cholestatic and fatty liver disease. Gut, 2022, 71, 194-209.	6.1	84
229	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging, 2021, 13, 23416-23434.	1.4	17
230	Klatskin-Mimicking Lesions. Diagnostics, 2021, 11, 1944.	1.3	2
231	Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International, 0, , .	0.2	0
232	A Myeloid Signature-Based Nomogram Predicts the Postoperative Recurrence of Intrahepatic Cholangiocarcinoma. Frontiers in Molecular Biosciences, 2021, 8, 742953.	1.6	2
233	Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer. ESMO Open, 2021, 6, 100275.	2.0	18
234	The progress of immune checkpoint therapy in primary liver cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188638.	3.3	29
237	Overexpression of HMGA1 confers radioresistance by transactivating RAD51 in cholangiocarcinoma. Cell Death Discovery, 2021, 7, 322.	2.0	9
238	Mucosalâ€associated invariant Tâ€cell tumor infiltration predicts longâ€term survival in cholangiocarcinoma. Hepatology, 2022, 75, 1154-1168.	3.6	14
239	The Impact of Histological Annotations for Accurate Tissue Classification Using Mass Spectrometry Imaging. Metabolites, 2021, 11, 752.	1.3	8
240	Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Frontiers in Oncology, 2021, 11, 777617.	1.3	5
241	Palliative surgical treatment of patients, suffering proximal tumoral affection of biliary ducts and the jaundice syndrome. Klinichna Khirurhiia, 2020, 87, 40-47.	0.0	0
242	The New Era of Immunotherapy in Bile Duct Cancer Management. , 0, , .		0

#	Article	IF	Citations
243	Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Cancer Control, 2020, 27, 107327482098301.	0.7	13
244	Targeted therapies in cholangiocarcinoma: emerging hope through novel trial design. British Journal of Surgery, 2022, 109, 239-241.	0.1	0
245	Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. Acta OncolÃ³gica, 2022, 61, 197-201.	0.8	2
246	Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial. Biomolecules, 2021, 11, 1626.	1.8	4
247	Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2022, 157, 59.	2.2	19
248	Recent advances in understanding cholangiocarcinoma. Faculty Reviews, 2020, 9, 15.	1.7	0
249	Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4). Biomedicine and Pharmacotherapy, 2022, 145, 112403.	2.5	4
250	Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Frontiers in Physiology, 2021, 12, 715536.	1.3	11
251	Emerging roles of circular RNAs in liver cancer. JHEP Reports, 2022, 4, 100413.	2.6	10
252	Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers, 2021, 13, 5709.	1.7	3
253	Non-surgical treatment of hilar cholangiocarcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 1696-1708.	0.8	10
254	The Smad4-MYO18A-PP1A complex regulates Î²-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma. Cell Death and Differentiation, 2022, 29, 818-831.	5.0	26
255	Latest advances in cholangiocarcinoma. Liver Cancer International, 0, , .	0.2	0
256	Stereotactic body radiation therapy for primary liver tumors: An effective liverâ€directed therapy in the toolbox. Cancer, 2022, 128, 956-965.	2.0	7
257	LIN28B Enhanced STAT3 Signaling Regulates Inflammatory Response and Chemotherapeutic Resistance in Cholangiocytes. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3671-3678.	0.5	3
258	Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/Î²-catenin signaling and inhibits apoptosis in cholangiocarcinoma. Cellular Oncology (Dordrecht), 2021, 44, 1351-1361.	2.1	28
259	Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. Journal of Hepatology, 2022, 76, 608-618.	1.8	62
260	Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern. Gut and Liver, 2022, 16, 613-624.	1.4	6

#	Article	IF	Citations
261	Anatomical reconstruction after pancreaticoduodenectomy in a patient with previous Rouxâ€enâ€Y gastric bypass for obesity: a novel complication for the future. ANZ Journal of Surgery, 2021, , .	0.3	0
262	Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies. Expert Review of Precision Medicine and Drug Development, 0, , 1-3.	0.4	0
263	Cholangiocarcinoma: what are the most valuable therapeutic targets â€“ cancer-associated fibroblasts, immune cells, or beyond T cells?. Expert Opinion on Therapeutic Targets, 2021, 25, 835-845.	1.5	8
264	Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling. Cancers, 2021, 13, 6049.	1.7	3
265	Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. Journal of Personalized Medicine, 2021, 11, 1270.	1.1	3
266	Assessment of robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect. Hepatobiliary Surgery and Nutrition, 2021, .	0.7	0
267	Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver International, 2022, 42, 492-506.	1.9	20
268	Cholangiopathies and the noncoding revolution. Current Opinion in Gastroenterology, 2022, 38, 128-135.	1.0	0
269	A2M is a potential core gene in intrahepatic cholangiocarcinoma. BMC Cancer, 2022, 22, 5.	1.1	5
272	Liquid biopsy: Precise diagnosis and therapy for cholangiocarcinoma. World Journal of Gastrointestinal Oncology, 2022, 14, 362-365.	0.8	0
273	Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell, 2022, 40, 70-87.e15.	7.7	120
274	Regorafenibâ€“avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. European Journal of Cancer, 2022, 162, 161-169.	1.3	22
275	Pleiotropic roles of FXR in liver and colorectal cancers. Molecular and Cellular Endocrinology, 2022, 543, 111543.	1.6	5
276	Recent advances in understanding cholangiocarcinoma. Faculty Reviews, 2020, 9, 15.	1.7	1
277	An Overview of the Tumor Microenvironment and Response to Immunotherapy in Gastrointestinal Malignancies. , 2021, , 3-28.		0
278	What are the key challenges in the pharmacological management of cholangiocarcinoma?. Expert Opinion on Pharmacotherapy, 2022, 23, 531-533.	0.9	2
279	Multiparametric <scp>MRI</scp>â€Based Radiomic Signature for Preoperative Evaluation of Overall Survival in Intrahepatic Cholangiocarcinoma After Partial Hepatectomy. Journal of Magnetic Resonance Imaging, 2022, 56, 739-751.	1.9	9
280	Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology, 2022, 29, 551-564.	0.9	6

#	Article	IF	Citations
281	The complexity of cholangiocarcinoma goes beyond clinical practice: Challenges in trials design and interpretation. Liver International, 2022, 42, 268-270.	1.9	0
282	Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma. PeerJ, 2022, 10, e12750.	0.9	5
283	Genetic Variant of CXCR1 (rs2234671) Associates with Clinical Outcome in Perihilar Cholangiocarcinoma. Liver Cancer, 2022, 11, 162-173.	4.2	9
284	Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opinion on Therapeutic Targets, 2022, 26, 79-92.	1.5	4
285	Laparoscopic Versus Open Surgery for Early-Stage Intrahepatic Cholangiocarcinoma After Mastering the Learning Curve: A Multicenter Data-Based Matched Study. Frontiers in Oncology, 2021, 11, 742544.	1.3	8
286	Imaging mimickers of cholangiocarcinoma: a pictorial review. Abdominal Radiology, 2022, 47, 981-997.	1.0	3
287	Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance. Clinical and Molecular Hepatology, 2022, 28, 396-407.	4.5	15
288	Reply. Hepatology, 2022, 75, 1058-1058.	3.6	0
289	Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less. Cancers, 2022, 14, 397.	1.7	11
290	Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach. Cancers, 2022, 14, 392.	1.7	7
291	In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma. Cancer Research, 2022, 82, 1548-1559.	0.4	8
292	Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?. Expert Opinion on Investigational Drugs, 2022, 31, 221-233.	1.9	5
293	Down-Regulation of C1GALT1 Enhances the Progression of Cholangiocarcinoma through Activation of AKT/ERK Signaling Pathways. Life, 2022, 12, 174.	1.1	5
294	CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma. Molecular Cancer, 2022, 21, 18.	7.9	22
296	Autophagy Regulation on Cancer Stem Cell Maintenance, Metastasis, and Therapy Resistance. Cancers, 2022, 14, 381.	1.7	17
297	Increasing Incidence of Intrahepatic Cholangiocarcinoma Relative to Hepatocellular Carcinoma in the United States. , 2022, 1, 121-124.		3
298	Treatment of Intrahepatic Cholangiocarcinomaâ€"A Multidisciplinary Approach. Cancers, 2022, 14, 362.	1.7	29
299	The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment. Current Opinion in Gastroenterology, 2022, 38, 136-143.	1.0	5

#	Article	IF	Citations
300	The impact of preoperative biliary drainage on postoperative outcomes in patients with malignant obstructive jaundice: a retrospective analysis of 290 consecutive cases at a single medical center. World Journal of Surgical Oncology, 2022, 20, 7.	0.8	12
301	Peroral Cholangioscopy-Guided Targeted Biopsy versus Conventional Endoscopic Transpapillary Forceps Biopsy for Biliary Stricture with Suspected Bile Duct Cancer. Journal of Clinical Medicine, 2022, 11, 289.	1.0	2
302	Short-Chain Fatty Acid Butyrate Induces Cilia Formation and Potentiates the Effects of HDAC6 Inhibitors in Cholangiocarcinoma Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 809382.	1.8	5
303	Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-ÎºB Signaling Pathways. Asian Pacific Journal of Cancer Prevention, 2022, 23, 115-123.	0.5	2
304	Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Future Oncology, 2022, , .	1.1	1
305	Noncoding RNAs in liver cancer patients. , 2022, , 343-389.		0
306	Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma. Journal of Clinical and Translational Hepatology, 2022, 10, 553-563.	0.7	9
307	Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology, 2022, 76, 1617-1633.	3.6	15
308	Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach. Genes, 2022, 13, 271.	1.0	5
309	Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). ESMO Open, 2022, 7, 100377.	2.0	8
310	How I treat biliary tract cancer. ESMO Open, 2022, 7, 100378.	2.0	45
311	Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction over 32-Month Follow-Up. Gastrointestinal Tumors, 2022, 9, 12-18.	0.3	2
312	TNF receptorâ€“related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NFâ€ºBâ€inducing kinaseâ€“mediated hepatocyte transdifferentiation. Hepatology, 2023, 77, 395-410.	3.6	7
313	Bile cellâ€free DNA: a game changer for management of biliary tract cancer?. ESMO Open, 2022, 7, 100389.	2.0	0
314	Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports, 2022, 4, 100417.	2.6	6
315	Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma. Hepatology, 2023, 77, 92-108.	3.6	13
316	Computed tomography findings in canine cholangiocellular carcinoma. Veterinary Record Case Reports, 0, , .	0.1	0
317	Theragnostics in primary and secondary liver tumors: the need for a personalized approach. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, .	0.4	5

#	Article	IF	Citations
318	Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 85-98.	1.5	12
319	Preoperative magnetic resonance imagingâ€based prognostic model for massâ€forming intrahepatic cholangiocarcinoma. Liver International, 2022, 42, 930-941.	1.9	7
320	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	1.8	119
321	It is the lymph node ratio that determines survival and recurrence patterns in resected distal cholangiocarcinoma. A multicenter international study. European Journal of Surgical Oncology, 2022, 48, 1576-1584.	0.5	7
322	Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research. Journal of Clinical and Translational Hepatology, 2022, 10, 700-710.	0.7	3
323	High-Molecular-Weight Fractions of Spruce and Eucalyptus Lignin as a Perspective Nanoparticle-Based Platform for a Therapy Delivery in Liver Cancer. Frontiers in Bioengineering and Biotechnology, 2021, 9, 817768.	2.0	11
324	Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature. Cancer Biology and Therapy, 2022, 23, 112-116.	1.5	10
325	Insulin therapy and biliary tract cancer: insights from real-world data. Endocrine Connections, 2022, , .	0.8	1
326	Prognostic value of Dickkopf-1 and ÃŸ-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer. Scientific Reports, 2022, 12, 1931.	1.6	2
327	Differential of cholangiocarcinoma disease using Raman spectroscopy combined with multivariate analysis. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 272, 121006.	2.0	13
328	Cholangiocarcinogenesis and targeted therapy for cholangiocarcinoma. Meditsinskiy Sovet, 2021, , 101-109.	0.1	0
329	Biliverdin reductase B impairs cholangiocarcinoma cell motility by inhibiting the Notch/Snail signaling pathway. Journal of Cancer, 2022, 13, 2159-2170.	1.2	2
330	Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities. Advances in Cancer Research, 2022, , .	1.9	1
331	Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances. Advances in Cancer Research, 2022, , .	1.9	2
332	Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. Advances in Cancer Research, 2022, , .	1.9	2
333	Novel insights into molecular and immune subtypes of biliary tract cancers. Advances in Cancer Research, 2022, , 167-199.	1.9	1
334	MICA/B-targeted antibody promotes NK cellâ€“driven tumor immunity in patients with intrahepatic cholangiocarcinoma. OncoImmunology, 2022, 11, 2035919.	2.1	13
335	Single-cell Transcriptomic Architecture Unraveling the Complexity of Tumor Heterogeneity in Distal Cholangiocarcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1592-1609.e9.	2.3	8

#	Article	IF	Citations
336	Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. Frontiers in Oncology, 2022, 12, 771418.	1.3	4
337	Pure laparoscopic major liver resection after yttrium90 radioembolization: a case-matched series analysis of feasibility and outcomes. Langenbeck's Archives of Surgery, 2022, 407, 1099-1111.	0.8	2
338	Editorial for â€œMultiparametric <scp>MRI</scp>â€Based Radiomic Signature for Preoperative Evaluation of Overall Survival in Intrahepatic Cholangiocarcinoma After Partial Hepatectomyâ€• Journal of Magnetic Resonance Imaging, 2022, 56, 752-753.	1.9	0
339	CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype. Journal of Experimental and Clinical Cancer Research, 2022, 41, 65.	3.5	7
340	Inhibition of Ceramide Glycosylation Enhances Cisplatin Sensitivity in Cholangiocarcinoma by Limiting the Activation of the ERK Signaling Pathway. Life, 2022, 12, 351.	1.1	4
341	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers, 2022, 14, 1154.	1.7	11
342	Administration of Iodine-125 Seeds Promotes Apoptosis in Cholangiocarcinoma through the PI3K/Akt Pathway. Advances in Polymer Technology, 2022, 2022, 1-6.	0.8	0
343	Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers, 2022, 14, 1026.	1.7	17
344	A Case Report of CHEK2 and MUTYH Germline Mutations Associated With Cholangiocarcinoma in a Young Patient. Cureus, 2022, 14, e22631.	0.2	2
345	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Journal of Hepatology, 2022, 77, 177-190.	1.8	11
346	Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma. Nature Communications, 2022, 13, 1642.	5.8	40
347	Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression. Hepatology, 2022, 76, 1302-1317.	3.6	13
348	Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Annals of Medicine, 2022, 54, 803-811.	1.5	9
349	Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study. Cancers, 2022, 14, 1730.	1.7	3
350	Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. Frontiers in Oncology, 2022, 12, 785535.	1.3	6
351	Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2022, 13, 801909.	2.2	4
352	Role of intraluminal brachytherapy in palliation of biliary obstruction in cholangiocarcinoma: A brief review. World Journal of Gastrointestinal Endoscopy, 2022, 14, 106-112.	0.4	0
353	Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway. Frontiers in Pharmacology, 2022, 13, 847905.	1.6	2

#	Article	IF	Citations
354	Lipid Metabolism in Biliary Tract Cancer: A New Therapeutic Target?. Annals of Surgical Oncology, 2022, 29, 2750-2751.	0.7	1
355	The Emerging Roles of LINC00665 in Human Cancers. Frontiers in Cell and Developmental Biology, 2022, 10, 839177.	1.8	5
356	Combination systemic therapies with immune checkpoint inhibitors in biliary tract cancer: effective but not enough?. Expert Review of Gastroenterology and Hepatology, 2022, 16, 307-310.	1.4	3
357	Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR Imaging Features and Its Prognostic Value. Liver Cancer, 2022, 11, 233-246.	4.2	8
358	Local palliative therapies for unresectable malignant biliary obstruction: radiofrequency ablation combined with stent or biliary stent alone? An updated meta-analysis of nineteen trials. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 5559-5570.	1.3	9
359	Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY. Expert Review of Gastroenterology and Hepatology, 2022, 16, 273-278.	1.4	2
360	Biology of IDH mutant cholangiocarcinoma. Hepatology, 2022, 75, 1322-1337.	3.6	20
361	Antitumor activity of T cells secreting Î±CD133-Î±CD3 bispecific T-cell engager against cholangiocarcinoma. PLoS ONE, 2022, 17, e0265773.	1.1	3
362	Lipid alterations in chronic liver disease and liver cancer. JHEP Reports, 2022, 4, 100479.	2.6	69
364	Exosomes in the tumor microenvironment of cholangiocarcinoma: current status and future perspectives. Journal of Translational Medicine, 2022, 20, 117.	1.8	11
365	Serum Angiopoietin-Like Protein 4: A Potential Prognostic Biomarker for Prediction of Vascular Invasion and Lymph Node Metastasis in Cholangiocarcinoma Patients. Frontiers in Public Health, 2022, 10, 836985.	1.3	2
366	Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 1789.	1.7	7
367	Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma. Frontiers in Medicine, 2022, 9, 857140.	1.2	23
368	KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. Cancer Cell International, 2022, 22, 128.	1.8	14
369	Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2022, 29, 5528-5538.	0.7	14
370	Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers. Cancers, 2022, 14, 1748.	1.7	22
371	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. Journal of Clinical Oncology, 2022, 40, 2048-2057.	0.8	65
372	Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development. Cancers, 2022, 14, 1442.	1.7	6

#	Article	IF	Citations
373	FGFR Inhibitors in Cholangiocarcinoma: A Real-World Experience at a Tertiary Center. JCO Precision Oncology, 2022, 6, e2100511.	1.5	0
374	Mutational signatures and processes in hepatobiliary cancers. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 367-382.	8.2	2
375	Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma. BMC Cancer, 2022, 22, 258.	1.1	18
376	Soluble TGFBI aggravates the malignancy of cholangiocarcinoma through activation of the ITGB1 dependent PPARI3 signalling pathway. Cellular Oncology (Dordrecht), 2022, 45, 275-291.	2.1	9
377	The Functional Roles of Immune Cells in Primary Liver Cancer. American Journal of Pathology, 2022, 192, 826-836.	1.9	17
379	CHST4 might promote the malignancy of cholangiocarcinoma. PLoS ONE, 2022, 17, e0265069.	1.1	0
380	Radiomics of Biliary Tumors: A Systematic Review of Current Evidence. Diagnostics, 2022, 12, 826.	1.3	11
381	Second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer: a new standard of care?. Expert Review of Gastroenterology and Hepatology, 2022, 16, 201-203.	1.4	0
382	Comparison of the Malignant Predictors in Intrahepatic and Extrahepatic Intraductal Papillary Neoplasm of the Bile Duct. Journal of Clinical Medicine, 2022, 11, 1985.	1.0	5
383	Work-Up and Outcome of Hepatic Resection for Peri-Hilar Cholangiocarcinoma (PH-CCA) without Staging Laparoscopy. Cancers, 2022, 14, 1841.	1.7	0
384	The 11th revision of the International Statistical Classification of Disease and Related Health Problems and Cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 276-279.	0.7	1
385	Circ_0000591 served as endogenous RNA for miR-326 to promote progression of cholangiocarcinoma via the TLR4/MyD88/IL6 axis. Biochemical and Biophysical Research Communications, 2022, 600, 101-108.	1.0	6
386	Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety. Future Oncology, 2022, 18, 2321-2338.	1.1	5
387	Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1â€“ Mediated Gemcitabine Chemoresistance. Frontiers in Oncology, 2022, 12, 860339.	1.3	6
388	Suppression of histone deacetylase 1 by JSL-1 attenuates the progression and metastasis of cholangiocarcinoma via the TPX2/Snail axis. Cell Death and Disease, 2022, 13, 324.	2.7	4
389	Liver Surgery: Important Considerations for Pre- and Postoperative Imaging. Radiographics, 2022, , 210124.	1.4	4
390	Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy. Journal of Clinical Medicine, 2022, 11, 2057.	1.0	1
391	A single center comparative retrospective study of in situ split plus portal vein ligation versus conventional two-stage hepatectomy for cholangiocellular carcinoma. Acta Chirurgica Belgica, 2023, 123, 384-395.	0.2	1

#	Article	IF	Citations
392	An overview of the pharmacological activities of scopoletin against different chronic diseases. Pharmacological Research, 2022, 179, 106202.	3.1	14
393	Role of Swiprosin-1/EFHD2 as a biomarker in the development of chronic diseases. Life Sciences, 2022, 297, 120462.	2.0	2
394	Right hepatic trisectionectomy combined total caudate lobectomy with non-touch technique for advanced hilar cholangiocarcinoma: A surgical case report (with video). International Journal of Surgery Case Reports, 2022, 94, 106987.	0.2	0
395	Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. , 2022, 237, 108170.		9
396	Homophilic Interaction of CD147 Promotes IL-6-Mediated Cholangiocarcinoma Invasion via the NF-Î°B-Dependent Pathway. International Journal of Molecular Sciences, 2021, 22, 13496.	1.8	11
398	Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways. Frontiers in Cell and Developmental Biology, 2021, 9, 796740.	1.8	18
399	Moving forward in the treatment of cholangiocarcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 1939-1955.	0.8	4
400	Epigenetic Silencing of 15-Hydroxyprostaglandin Dehydrogenase by Histone Methyltransferase EHMT2/G9a in Cholangiocarcinoma. Molecular Cancer Research, 2022, 20, 350-360.	1.5	3
401	Bioinformatic Prediction of Novel Signaling Pathways of Apoptosis-inducing Factor, Mitochondrion-associated 3 (AIFM3) and Their Roles in Metastasis of Cholangiocarcinoma Cells. Cancer Genomics and Proteomics, 2022, 19, 35-49.	1.0	2
402	Biological therapies in patients with liver disease: are they really lifesavers?. Expert Opinion on Biological Therapy, 2022, 22, 473-490.	1.4	0
403	The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma. Cancers, 2021, 13, 6272.	1.7	1
404	PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma. Cancer Cell International, 2021, 21, 657.	1.8	6
405	Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression. Cell Death and Disease, 2021, 12, 1158.	2.7	15
406	Impact of cirrhosis on longâ€term survival outcomes of patients with intrahepatic cholangiocarcinoma. Cancer Medicine, 2022, , .	1.3	2
407	MiRNA-196-5p Promotes Proliferation and Migration in Cholangiocarcinoma via HAND1/Wnt/Î²-Catenin Signaling Pathway. Journal of Oncology, 2022, 2022, 1-10.	0.6	1
408	The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of Gastrointestinal Cancer, 2023, 54, 492-500.	0.6	3
409	The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis. International Journal of Clinical Oncology, 2022, 27, 1188-1195.	1.0	3
410	Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells. Scientific Reports, 2022, 12, 6154.	1.6	12

#	Article	IF	Citations
411	Multidetector CT of Extrahepatic Bile Duct Cancer: Diagnostic Performance of Tumor Resectability and Interreader Agreement. Radiology, 2022, 304, 96-105.	3.6	4
412	Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study. Cancers, 2022, 14, 1950.	1.7	3
413	Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer, 2022, 128, 2529-2539.	2.0	7
414	Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Biology, 2022, 11, 585.	1.3	5
415	Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. BMC Cancer, 2022, 22, 423.	1.1	10
416	The Role of Herbal Medicine in Cholangiocarcinoma Control: A Systematic Review. Planta Medica, 2023, 89, 3-18.	0.7	3
417	Concurrent Activation of Kras and Canonical Wnt Signaling Induces Premalignant Lesions That Progress to Extrahepatic Biliary Cancer in Mice. Cancer Research, 2022, 82, 1803-1817.	0.4	7
418	Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.. American Journal of Translational Research (discontinued), 2021, 13, 13246-13260.	0.0	0
419	Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210968.	1.4	8
420	Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy, 0, , 200-223.	0.5	7
421	Predicting Disease-Specific Survival for Patients With Primary Cholangiocarcinoma Undergoing Curative Resection by Using a Decision Tree Model. Frontiers in Oncology, 2022, 12, 824541.	1.3	4
422	Updates in Cholangiocarcinoma. Journal of the Advanced Practitioner in Oncology, 2022, 13, 320-323.	0.2	4
423	PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 2190.	1.7	4
424	Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 890605.	1.8	5
425	Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma. Cancers, 2022, 14, 2120.	1.7	10
426	An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. Life, 2022, 12, 665.	1.1	11
427	Î²-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology, 2022, 163, 481-494.	0.6	13
428	Human branching cholangiocyte organoids recapitulate functional bile duct formation. Cell Stem Cell, 2022, 29, 776-794.e13.	5.2	17

#	Article	IF	Citations
429	Mesenchymal stem cellâ€'derived exosomes loaded with 5â€'Fu against cholangiocarcinoma inÂvitro. Molecular Medicine Reports, 2022, 25, .	1.1	7
430	Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicology in Vitro, 2022, 82, 105385.	1.1	3
431	ROBO1 p.E280* Loses the Inhibitory Effects on the Proliferation and Angiogenesis of Wild-Type ROBO1 in Cholangiocarcinoma by Interrupting SLIT2 Signal. Frontiers in Oncology, 2022, 12, .	1.3	2
432	Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. Cancers, 2022, 14, 2381.	1.7	4
433	Bridging the equity gap in patient education: the biliary tract cancer BABEL project. Lancet Oncology, The, 2022, 23, 568-570.	5.1	1
434	Comprehensive Evaluation and Application of a Novel Method to Isolate Cell-Free DNA Derived From Bile of Biliary Tract Cancer Patients. Frontiers in Oncology, 2022, 12, .	1.3	2
435	Stromal yinâ€yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma. Hepatology, 2022, , .	3.6	0
436	Prognostic significance of gammaâ€glutamyl transpeptidase to albumin ratio in patients with intrahepatic cholangiocarcinoma after hepatectomy. Journal of Cellular and Molecular Medicine, 2022, 26, 3196-3202.	1.6	5
437	Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 2208.	1.7	10
438	Joining the dots â€“ NEDDylation in cancer cells regulates the tumour environment in cholangiocarcinoma. Journal of Hepatology, 2022, , .	1.8	0
439	Prognostic Significance of Growth Pattern in Predicting Outcome of Opisthorchis viverrini-Associated Distal Cholangiocarcinoma in Thailand. Frontiers in Public Health, 2022, 10, .	1.3	4
440	The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma. Frontiers in Oncology, 2022, 12, .	1.3	8
441	Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety. CardioVascular and Interventional Radiology, 2022, 45, 1092-1101.	0.9	6
442	Fluorescence in situ hybridization detection of chromosome 7 and/or 17 polysomy as a prognostic marker for cholangiocarcinoma. Scientific Reports, 2022, 12, 8441.	1.6	1
443	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748.	6.1	42
444	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut, 2022, , gutjnl-2022-327099.	6.1	11
445	Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment. Technology in Cancer Research and Treatment, 2022, 21, 153303382210972.	0.8	0
446	Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment. Theranostics, 2022, 12, 3911-3927.	4.6	3

#	Article	IF	Citations
447	Metabolic reprogramming in cholangiocarcinoma. Journal of Hepatology, 2022, 77, 849-864.	1.8	49
448	Characterization of the Estrogen Response Helps to Predict Prognosis and Identify Potential Therapeutic Targets in Cholangiocarcinoma. Frontiers in Oncology, 2022, 12, .	1.3	0
449	Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. British Journal of Cancer, 2022, 127, 649-660.	2.9	23
451	Differential Plasma Proteomes of the Patients with Opisthorchiasis Viverrini and Cholangiocarcinoma Identify Polymeric Immunoglobulin Receptor as a Potential Biomarker. SSRN Electronic Journal, 0, , .	0.4	0
452	Expressional and prognostic value of <scp>HPCAL1</scp> in cholangiocarcinoma via integrated bioinformatics analyses and experiments. Cancer Medicine, 0, , .	1.3	1
453	Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors. Cancers, 2022, 14, 2666.	1.7	6
454	HMGN3 represses transcription of epithelial regulators to promote migration of cholangiocarcinoma in a SNAI2â€dependent manner. FASEB Journal, 2022, 36, .	0.2	3
455	New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	9
456	Successful Treatment of Intrahepatic Cholangiocarcinoma With Liver/Lung Metastasis and Peritoneal Dissemination After Liver Resection. Anticancer Research, 2022, 42, 3209-3215.	0.5	0
457	Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma. Cancers, 2022, 14, 2641.	1.7	11
458	Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma. British Journal of Cancer, 2022, 127, 757-765.	2.9	7
459	The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	10
460	Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. Life, 2022, 12, 829.	1.1	8
461	Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mTOR signaling pathway in human cholangiocarcinoma QBC939 cells. Journal of Gastrointestinal Oncology, 2021, .	0.6	0
462	Treatment of biliary tract carcinoma over the last 30 years. BioScience Trends, 2022, 16, 189-197.	1.1	2
463	Prediction of Angiopoietin-like Protein 4-related Signaling Pathways in Cholangiocarcinoma Cells. Cancer Genomics and Proteomics, 2022, 19, 490-502.	1.0	1
464	Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link. Annals of Global Health, 2022, 88, .	0.8	3
465	Treatment Status and Progress of Hilar Cholangiocarcinoma. Advances in Clinical Medicine, 2022, 12, 5375-5381.	0.0	0

#	Article	IF	Citations
466	Involvement of Epigenomic Factors in Bile Duct Cancer. Seminars in Liver Disease, 2022, 42, 202-211.	1.8	0
467	Modification of the AJCC/UICC 8th edition staging system for intrahepatic cholangiocarcinoma: proposal for an alternative staging system from cholangiocarcinoma-prevalent Northeast Thailand. Hpb, 2022, 24, 1944-1956.	0.1	6
468	Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open, 2022, 7, 100503.	2.0	8
469	Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort. CardioVascular and Interventional Radiology, 2022, 45, 1117-1128.	0.9	10
470	Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancerâ€"Current Treatment Options and Future Perspectives. International Journal of Molecular Sciences, 2022, 23, 6664.	1.8	13
471	Proteogenomic characterization of cholangiocarcinoma. Hepatology, 2023, 77, 411-429.	3.6	12
472	Role of molecular genetics in the clinical management of cholangiocarcinoma. ESMO Open, 2022, 7, 100505.	2.0	15
473	Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2Î±, and HIF-1Î±. International Journal of Molecular Sciences, 2022, 23, 6353.	1.8	2
474	Bile duct dysplasia and associated invasive carcinoma: clinicopathological features, diagnosis, and practical challenges. Human Pathology, 2022, , .	1.1	1
475	Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. Journal of Hepatology, 2022, 77, 1359-1372.	1.8	30
476	Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. Journal of Hepatology, 2022, 77, 1047-1058.	1.8	7
477	Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma. BMC Gastroenterology, 2022, 22, .	0.8	1
478	Ramucirumab or merestinib in biliary tract cancer: new combinations, old mistakes?. Expert Review of Precision Medicine and Drug Development, 2022, 7, 60-61.	0.4	0
479	Cholangiocarcinoma: The Present and Future of Targeted Therapies. Touch Reviews in Oncology & Haematology, 2022, 18, 9.	0.1	0
480	Genomic Characteristics, Metabolic Signature and Immune Microenvironment of <i>Clonorchis Sinensis</i>-Related Intrahepatic Cholangiocarcinoma. SSRN Electronic Journal, 0, , .	0.4	0
481	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precision Oncology, 2022, , .	1.5	4
482	Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. Journal of Personalized Medicine, 2022, 12, 1086.	1.1	5
483	Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations. Cancers, 2022, 14, 3156.	1.7	0

#	Article	IF	Citations
484	Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?. Gut, 0, , gutjnl-2022-327782.	6.1	1
485	Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification. Molecular Medicine, 2022, 28, .	1.9	2
486	The focus clinical research in intrahepatic cholangiocarcinoma. European Journal of Medical Research, 2022, 27, .	0.9	7
487	Effects of portal vein resection and hepatic artery resection on long-term survival in Klatskin tumor: a meta-analysis. World Journal of Surgical Oncology, 2022, 20, .	0.8	4
488	KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasisâ€free survival and reduced Eâ€cadherin expression. Liver International, 2022, 42, 2329-2340.	1.9	4
489	Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances. Frontiers in Oncology, 0, 12, .	1.3	3
490	Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Annals of Hepatology, 2022, 27, 100737.	0.6	43
491	Human chorion-derived mesenchymal stem cells suppress JAK2/STAT3 signaling and induce apoptosis of cholangiocarcinoma cell lines. Scientific Reports, 2022, 12, .	1.6	1
492	Wnt signaling in liver regeneration, disease, and cancer. Clinical and Molecular Hepatology, 2023, 29, 33-50.	4.5	8
493	Prognostic Significance of the Systemic Immune-Inflammation Index in Patients With Cholangiocarcinoma: A Meta-Analysis. Frontiers in Oncology, 0, 12, .	1.3	6
494	An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	4
495	Precision Medicine in Biliary Tract Cancer. Journal of Clinical Oncology, 2022, 40, 2716-2734.	0.8	12
496	Update on Cholangiocarcinoma. Digestive Disease Interventions, 0, , .	0.3	0
497	Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. Frontiers in Immunology, 0, 13, .	2.2	9
498	Morphomolecular Classification Update on Hepatocellular Adenoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma. Radiographics, 2022, 42, 1338-1357.	1.4	4
500	Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies. Cancers, 2022, 14, 3455.	1.7	6
501	Patient reported outcomes: Financial toxicity is a barrier to clinical trials and personalized therapy in cholangiocarcinoma. Journal of Surgical Oncology, 2022, 126, 1003-1010.	0.8	3
502	Low expression and Hypermethylation of ATP2B1 in Intrahepatic Cholangiocarcinoma Correlated With Cold Tumor Microenvironment. Frontiers in Oncology, 0, 12, .	1.3	2

#	Article	IF	Citations
503	Identification of publication characteristics and research trends in the management of gallbladder cancer. , 2022, 1, 127-138.		0
504	Impact of lncRNA SOX9-AS1 overexpression on the prognosis and progression of intrahepatic cholangiocarcinoma. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101999.	0.7	2
505	Selective Internal Radiotherapy Changes the Immune Profiles of Extracellular Vesicles and Their Immune Origin in Patients with Inoperable Cholangiocarcinoma. Cells, 2022, 11, 2309.	1.8	6
506	Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Frontiers in Oncology, 0, 12, .	1.3	7
507	Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells. Biology, 2022, 11, 1098.	1.3	2
508	Combined Intraoperative Biliary Stent with Choledochoduodenostomy: a Simplified Technique for Intraoperatively Found Advanced Perihilar Bile Duct Tumor Involving Both Hepatic Ducts. Indian Journal of Surgery, 2022, 84, 546-550.	0.2	1
509	In Silico Target Identification of Galangin, as an Herbal Flavonoid against Cholangiocarcinoma. Molecules, 2022, 27, 4664.	1.7	1
510	Cancer-associated fibroblasts in the single-cell era. Nature Cancer, 2022, 3, 793-807.	5.7	141
511	Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence. Cancers, 2022, 14, 3483.	1.7	0
512	Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center. Current Oncology, 2022, 29, 5084-5090.	0.9	3
513	Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. Frontiers in Pharmacology, 0, 13, .	1.6	1
514	Therapeutic Effect of Regional Chemotherapy in Diffuse Metastatic Cholangiocarcinoma. Cancers, 2022, 14, 3701.	1.7	0
515	Neoadjuvant and Adjuvant Chemotherapy for Cholangiocarcinoma. The Korean Journal of Pancreas and Biliary Tract, 2022, 27, 111-115.	0.0	1
516	The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis. Scientific Reports, 2022, 12, .	1.6	7
517	Review of Mass-Forming Intrahepatic Cholangiocarcinoma. Korean Journal of Abdominal Radiology, 2022, 6, 1-11.	0.0	0
518	Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis. Journal of Personalized Medicine, 2022, 12, 1247.	1.1	2
519	Eriodictyol Attenuates Cholangiocarcinoma Malignancy by Regulating HMOX1 Expression: An In Vitro Study. Anticancer Research, 2022, 42, 3789-3798.	0.5	1
520	Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2233-2241.	0.5	4

#	Article	IF	Citations
521	<scp>DKK1</scp> drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with <scp>antiâ€ÐKK1</scp> therapeutic <scp>DKN</scp>â€01. Liver International, 2023, 43, 208-220.	1.9	7
522	The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence. Discover Oncology, 2022, 13, .	0.8	0
523	Multiple Cancer Combating by Natural Bioactives: A Review. Current Cancer Therapy Reviews, 2022, 18, .	0.2	0
524	Advances of cancer-associated fibroblasts in liver cancer. Biomarker Research, 2022, 10, .	2.8	21
525	Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. Npj Precision Oncology, 2022, 6, .	2.3	5
527	Examination on the risk factors of cholangiocarcinoma: A Mendelian randomization study. Frontiers in Pharmacology, 0, 13, .	1.6	5
528	Stereotactic radiotherapy for intrahepatic cholangiocarcinoma. World Journal of Gastrointestinal Oncology, 2022, 14, 1478-1489.	0.8	4
529	Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review. Frontiers in Oncology, 0, 12, .	1.3	1
530	The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma. Surgical Pathology Clinics, 2022, , .	0.7	0
531	Biomarkers for response to immunotherapy in hepatobiliary malignancies. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 413-419.	0.6	12
532	BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	10
533	Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study. Cancers, 2022, 14, 3921.	1.7	4
534	Diagnostic and prognostic nomograms for newly diagnosed intrahepatic cholangiocarcinoma with brain metastasis: A population-based analysis. Experimental Biology and Medicine, 2022, 247, 1657-1669.	1.1	1
535	Imaging Features of Premalignant Biliary Lesions and Predisposing Conditions with Pathologic Correlation. Radiographics, 0, , .	1.4	7
536	High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma. Frontiers in Public Health, 0, 10, .	1.3	3
537	Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. Journal of Hepatology, 2022, 77, 1586-1597.	1.8	12
538	Current Trends in Inpatient Care and In-Hospital Mortality of Cholangiocarcinoma in Germany: A Systematic Analysis between 2010 and 2019. Cancers, 2022, 14, 4038.	1.7	0
539	Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the <scp>U</scp>nited <scp>S</scp>tates. Cancer, 2022, 128, 3610-3619.	2.0	4

#	Article	IF	Citations
540	Minimally Invasive Injectable Thermochemical Ablation Therapy of Malignant Tumor via Alkali Metal Fluid. , 0, , .		0
541	Interleukin-6-derived cancer-associated fibroblasts activate STAT3 pathway contributing to gemcitabine resistance in cholangiocarcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	5
542	Current epidemiology of cholangiocarcinoma in Western countries. Journal of Hepatology, 2022, 77, 1690-1698.	1.8	39
543	Invited Commentary: Early Detection of Biliary Malignancies: Are We There Yet?. Radiographics, 0, , .	1.4	0
544	An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma. Oncologist, 2022, 27, 884-891.	1.9	3
545	Cold plasma endoscopy applied to biliary ducts: feasibility risk assessment on human-like and porcine models for the treatment of cholangiocarcinoma. Journal Physics D: Applied Physics, 2022, 55, 455401.	1.3	7
546	Preoperative cachexia index can predict the prognosis of extrahepatic biliary tract cancer after resection. Surgical Oncology, 2022, 44, 101825.	0.8	5
547	Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine. Translational Oncology, 2022, 25, 101514.	1.7	11
548	Molecular diagnostics and biomarkers in cholangiocarcinoma. Surgical Oncology, 2022, 44, 101851.	0.8	3
549	Immunotherapy for hepatobiliary malignancies: Progress and prospective. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 409-412.	0.6	6
550	Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. Npj Precision Oncology, 2022, 6, .	2.3	15
551	AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2023, 77, 659-702.	3.6	68
552	Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: Results from a German tertiary center. Pathology Research and Practice, 2022, 238, 154126.	1.0	2
553	Albendazole-induced autophagy blockade contributes to elevated apoptosis in cholangiocarcinoma cells through AMPK/mTOR activation. Toxicology and Applied Pharmacology, 2022, 454, 116214.	1.3	4
554	Unraveling the actin cytoskeleton in the malignant transformation of cholangiocyte biology. Translational Oncology, 2022, 26, 101531.	1.7	0
555	A Combination Therapy of Bortezomib, CXCR4 Inhibitor and Checkpoint Inhibitor is Effective in Cholangiocarcinoma in vivo. SSRN Electronic Journal, 0, , .	0.4	0
556	Viszeralchirurgie. , 2022, , 223-437.		0
557	Arid1a mutation suppresses TGF-Î² signaling and induces cholangiocarcinoma. Cell Reports, 2022, 40, 111253.	2.9	14

#	Article	IF	Citations
558	Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer. Cancers, 2022, 14, 4211.	1.7	6
559	Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma. Genes, 2022, 13, 1479.	1.0	4
560	Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial. Cancers, 2022, 14, 4229.	1.7	4
561	The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-7.	0.8	6
562	Identification of a prognosis-related ceRNA network in cholangiocarcinoma and potentially therapeutic molecules using a bioinformatic approach and molecular docking. Scientific Reports, 2022, 12, .	1.6	1
563	Elucidating the mechanism behind and investigating the efficacy of Traditional Chinese Medicine and Traditional Tibetan Medicine in combination with standard therapeutics in hepatocellular carcinoma and cholangiocarcinoma in vitro. Frontiers in Pharmacology, 0, 13, .	1.6	2
564	Identification of Novel Ribonucleotide Reductase Inhibitors for Therapeutic Application in Bile Tract Cancer: An Advanced Pharmacoinformatics Study. Biomolecules, 2022, 12, 1279.	1.8	1
565	Current and emerging immunotherapeutic approaches for biliary tract cancers. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 440-449.	0.6	9
566	Silmitasertib plus gemcitabine and cisplatin firstâ€line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology, 2023, 77, 760-773.	3.6	7
567	Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase <scp>II</scp> study. Cancer Medicine, 2023, 12, 4137-4146.	1.3	8
568	Surgical Treatment of Distal Cholangiocarcinoma. Current Oncology, 2022, 29, 6674-6687.	0.9	6
569	Identification of Prognostic Factors in Cholangiocarcinoma Based on Integrated ceRNA Network Analysis. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-15.	0.7	3
570	Pan-cancer analysis of Chromobox (CBX) genes for prognostic significance and cancer classification. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166561.	1.8	7
571	Clinical impact of bileâ€derived exosomal <scp>microRNAs</scp> as novel diagnostic and prognostic biomarkers for biliary tract cancers. Cancer Science, 2023, 114, 295-305.	1.7	5
572	Role of genetic testing in hepatic, pancreatic, and biliary cancers. Surgical Oncology, 2022, 44, 101844.	0.8	7
573	Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
574	Systemic Therapy Is Associated with Improved Oncologic Outcomes in Resectable Stage II/III Intrahepatic Cholangiocarcinoma: An Examination of the National Cancer Database over the Past Decade. Cancers, 2022, 14, 4320.	1.7	1
575	miR-188-5p and Host MALAT1 Regulate RBE Cell Migration, Invasion, and Apoptosis via Up-regulating PSMD10 in Cholangiocarcinoma. Applied Biochemistry and Biotechnology, 0, , .	1.4	0

#	Article	IF	Citations
576	LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma. Journal of Hepatology, 2023, 78, 142-152.	1.8	4
577	Tumor-Promoting Activity and Proteomic Profiling of Cisplatin/Oxaliplatin-Derived DAMPs in Cholangiocarcinoma Cells. International Journal of Molecular Sciences, 2022, 23, 10540.	1.8	2
578	Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma. Acta Biochimica Et Biophysica Sinica, 2022, , .	0.9	1
579	The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Annals of Oncology, 2022, 33, 1269-1283.	0.6	44
580	Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology, 2023, 77, 1943-1957.	3.6	5
581	Immunotherapy improved cancer related pain management in patients with advanced Hepato-Pancreatic Biliary Cancers: A propensity score-matched (PSM) analysis. Frontiers in Oncology, 0, 12, .	1.3	1
582	IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?. International Journal of Molecular Sciences, 2022, 23, 10869.	1.8	5
584	Knockout of liver fluke granulin, Ov-grn-1, impedes malignant transformation during chronic infection with Opisthorchis viverrini. PLoS Pathogens, 2022, 18, e1010839.	2.1	7
585	Immunobiology of the biliary tract system. Journal of Hepatology, 2022, 77, 1657-1669.	1.8	3
586	Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. British Journal of Cancer, 0, , .	2.9	2
587	Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	4
588	Defining Facility Volume Threshold for Optimization of Short- and Long-Term Outcomes in Patients Undergoing Resection of Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2023, 27, 730-740.	0.9	5
589	Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. Targeted Oncology, 2022, 17, 529-538.	1.7	4
590	Rational development of combination therapies for biliary tract cancers. Journal of Hepatology, 2023, 78, 217-228.	1.8	15
591	Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Frontiers in Immunology, 0, 13, .	2.2	8
592	Quantitative Proteomics Reveals Down-Regulated Glycolysis/Gluconeogenesis in the Large-Duct Type Intrahepatic Cholangiocarcinoma. Journal of Proteome Research, 2022, 21, 2504-2514.	1.8	4
593	Liver organoids: an in vitro 3D model for liver cancer study. Cell and Bioscience, 2022, 12, .	2.1	13
594	Differential plasma proteomes of the patients with Opisthorchiasis viverrini and cholangiocarcinoma identify a polymeric immunoglobulin receptor as a potential biomarker. Heliyon, 2022, 8, e10965.	1.4	0

#	Article	IF	Citations
595	Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study. Frontiers in Oncology, 0, 12, .	1.3	1
596	MC-GAT: multi-layer collaborative generative adversarial transformer for cholangiocarcinoma classification from hyperspectral pathological images. Biomedical Optics Express, 2022, 13, 5794.	1.5	7
597	Feasibility and Efficacy of Adjuvant Chemotherapy With Gemcitabine After Liver Transplantation for Perihilar Cholangiocarcinoma - A Multi-Center, Randomized, Controlled Trial (pro-duct001). Frontiers in Oncology, 0, 12, .	1.3	7
598	Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. , 2022, , 1-33.		0
599	Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. , 2022, , 125-200.		0
600	Identification and Validation of Novel Biomarkers and Potential Targeted Drugs in Cholangiocarcinoma: Bioinformatics, Virtual Screening, and Biological Evaluation. Journal of Microbiology and Biotechnology, 2022, 32, 1262-1274.	0.9	1
601	Proteomic and Phosphoproteomic Profiling Reveals the Oncogenic Role of Protein Kinase D Family Kinases in Cholangiocarcinoma. Cells, 2022, 11, 3088.	1.8	4
602	Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities. Cancer Communications, 2022, 42, 1049-1082.	3.7	28
603	MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells. Journal of Hepatology, 2023, 78, 364-375.	1.8	8
604	Piperlongumine and bortezomib synergically inhibit cholangiocarcinoma via ER stressâ€“induced cell death. Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396, 109-120.	1.4	2
605	Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. Medicina (Lithuania), 2022, 58, 1543.	0.8	1
606	Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort. Journal of Oncology, 2022, 2022, 1-16.	0.6	2
607	The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma. Expert Opinion on Therapeutic Targets, 0, , 1-9.	1.5	1
608	Establishment and Characterization of a New Human Intrahepatic Cholangiocarcinoma Cell Line LIV27. Cancers, 2022, 14, 5080.	1.7	0
609	Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention. Clinical Cancer Research, 2022, 28, 5359-5367.	3.2	5
610	Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
611	Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma. Cancers, 2022, 14, 5062.	1.7	0
612	Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers. Frontiers in Immunology, 0, 13, .	2.2	5

#	Article	IF	Citations
613	Association of gut microbiome and primary liver cancer: A twoâ€sample Mendelian randomization and caseâ€“control study. Liver International, 2023, 43, 221-233.	1.9	18
614	Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress. Current Oncology, 2022, 29, 7925-7931.	0.9	2
615	Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma. Hepatology International, 2023, 17, 77-85.	1.9	2
616	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. Frontiers in Oncology, 0, 12, .	1.3	1
617	Long-term morbidity after surgery for perihilar cholangiocarcinoma: A cohort study. Surgical Oncology, 2022, 45, 101875.	0.8	1
618	Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study. F1000Research, 0, 11, 1212.	0.8	0
619	Pathologies of Precursor Lesions of Biliary Tract Carcinoma. Cancers, 2022, 14, 5358.	1.7	10
620	MLN2238 exerts its anti-tumor effects via regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	1
621	Real-World Analysis of Treatment Patterns, Healthcare Utilization, Costs, and Mortality Among People with Biliary Tract Cancers in the USA. Advances in Therapy, 2022, 39, 5530-5545.	1.3	2
622	An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma. Expert Opinion on Pharmacotherapy, 2022, 23, 1879-1885.	0.9	1
623	Outcomes After Liver Transplantation With Incidental Cholangiocarcinoma. Transplant International, 0, 35, .	0.8	3
624	Predictive risk-score model to select patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy. Hpb, 2023, 25, 229-238.	0.1	0
625	Cancer-Associated Fibroblasts in Cholangiocarcinoma: Current Knowledge and Possible Implications for Therapy. Journal of Clinical Medicine, 2022, 11, 6498.	1.0	7
626	Kruppel-like factor 9 inhibits growth and metastasis of cholangiocarcinoma cells by targeted regulation of metallothionein 1ÂM transcription. Tissue and Cell, 2022, 79, 101962.	1.0	1
627	Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1149-1169.	1.8	3
628	Liver transplantation and intrahepatic cholangiocarcinoma: time to go forward again?. Current Opinion in Organ Transplantation, 2022, 27, 320-328.	0.8	2
629	Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation. Clinical Cancer Research, 2023, 29, 432-445.	3.2	2
630	FUT8 is regulated by miRâ€122â€5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling. Cellular Oncology (Dordrecht), 2023, 46, 79-91.	2.1	6

#	Article	IF	Citations
631	Role of the PP2A Pathway in Cholangiocarcinoma: State of the Art and Future Perspectives. Cancers, 2022, 14, 5422.	1.7	2
632	Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34, 127-140.	0.6	119
633	Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
634	Circular RNAs in cholangiocarcinoma. Cancer Letters, 2023, 553, 215980.	3.2	11
635	[18F]FAPI PET/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 937-950.	3.3	12
636	Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors. International Journal of Molecular Sciences, 2022, 23, 13612.	1.8	4
637	Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells. Cytotherapy, 2023, 25, 148-161.	0.3	5
638	Development of extrahepatic bile ducts and mechanisms of tumorigenesis: Lessons from mouse models. Pathology International, 2022, 72, 589-605.	0.6	4
639	Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer. Cancers, 2022, 14, 5425.	1.7	11
640	Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. Journal of Hepatology, 2023, 78, 652-657.	1.8	7
641	Bile detection of squamous cell carcinoma antigen (SCCA) in extrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2023, 55, 534-540.	0.4	3
642	Novel Mathematical Diagnostic Analysis of Malignant Biliary Stenosis Using Magnetic Resonance Cholangiography in Patients Undergoing Pancreaticoduodenectomy. Cancer Diagnosis & Prognosis, 2022, 2, 668-680.	0.3	0
643	Scalable Production of Size-Controlled Cholangiocyte and Cholangiocarcinoma Organoids within Liver Extracellular Matrix-Containing Microcapsules. Cells, 2022, 11, 3657.	1.8	3
644	Impact of adjuvant therapy on outcomes after curativeâ€intentÂresection for distal cholangiocarcinoma. Journal of Surgical Oncology, 0, , .	0.8	1
645	JUND/linc00976 promotes cholangiocarcinoma progression and metastasis, inhibits ferroptosis by regulating the miR-3202/GPX4 axis. Cell Death and Disease, 2022, 13, .	2.7	19
646	Cholangiocellular carcinoma occurrence after HCV eradication therapy: case series and review of the literature. Journal of Medicine and Life, 2022, 15, 1257-1266.	0.4	0
647	SHH/GLI2-TGF-Î²1 feedback loop between cancer cells and tumor-associated macrophages maintains epithelial-mesenchymal transition and endoplasmic reticulum homeostasis in cholangiocarcinoma. Pharmacological Research, 2023, 187, 106564.	3.1	4
648	Rare histotypes of epithelial biliary tract tumors: A literature review. Critical Reviews in Oncology/Hematology, 2023, 181, 103892.	2.0	5

#	Article	IF	Citations
649	Diagnosis of hepatocellular carcinoma using deep network with multi-view enhanced patterns mined in contrast-enhanced ultrasound data. Engineering Applications of Artificial Intelligence, 2023, 118, 105635.	4.3	4
650	Distal cholangiocarcinoma: case report and brief review of the literature. Radiology Case Reports, 2023, 18, 423-429.	0.2	0
651	Small duct type intrahepatic cholangiocarcinoma with extensive intraductal extension mimics an intraductal tubulopapillary neoplasm. Human Pathology Reports, 2023, 31, 300687.	0.1	0
652	Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update. Intractable and Rare Diseases Research, 2022, 11, 161-172.	0.3	5
653	Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
654	Establishment and validation of a prognostic nomogram for extrahepatic cholangiocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
655	Locoregional Approaches in Cholangiocarcinoma Treatment. Cancers, 2022, 14, 5853.	1.7	5
656	Integrating cell interaction with transcription factors to obtain a robust gene panel for prognostic prediction and therapies in cholangiocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
658	Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-Î² inhibition. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	4
659	Anticancer Activity of (Â±)-Kusunokinin Derivatives towards Cholangiocarcinoma Cells. Molecules, 2022, 27, 8291.	1.7	3
660	Antitumor Effects of Delta (9)-Tetrahydrocannabinol and Cannabinol on Cholangiocarcinoma Cells and Xenograft Mouse Models. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-14.	0.5	2
661	What is the management of resected cholangiocarcinoma in terms of intra- and postoperative status of tumor margins and lymph nodes? A current view. Expert Review of Gastroenterology and Hepatology, 2022, 16, 1019-1022.	1.4	0
662	Role of Machine Learning in Precision Oncology: Applications in Gastrointestinal Cancers. Cancers, 2023, 15, 63.	1.7	9
663	EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes. American Journal of Pathology, 2022, 192, 1712-1724.	1.9	3
664	Laparoscopic versus open hepatectomy for intrahepatic cholangiocarcinoma in patients aged 60 and older: a retrospective cohort study. World Journal of Surgical Oncology, 2022, 20, .	0.8	2
665	Inhibition of dopamine receptor <scp>D1</scp> signaling promotes human bile duct cancer progression via <scp>WNT</scp> signaling. Cancer Science, 2023, 114, 1324-1336.	1.7	4
666	Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy. Frontiers in Immunology, 0, 13, .	2.2	2
667	Pixel-Level Clustering of Hematoxylinâ€“Eosin-Stained Sections of Mouse and Human Biliary Tract Cancer. Biomedicines, 2022, 10, 3133.	1.4	1

#	Article	IF	Citations
668	The Role of Single-Nucleotide Polymorphisms in Cholangiocarcinoma: A Systematic Review. Cancers, 2022, 14, 5969.	1.7	4
669	The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review. Frontiers in Oncology, 0, 12, .	1.3	0
670	Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine. European Medical Journal Oncology, 0, , 2-11.	0.0	0
671	Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand. Frontiers in Oncology, 0, 12, .	1.3	0
672	Identification of therapeutic targets and prognostic biomarkers in cholangiocarcinoma via WGCNA. Frontiers in Oncology, 0, 12, .	1.3	2
673	Intra-Tumoral Secondary Follicle-like Tertiary Lymphoid Structures Are Associated with a Superior Prognosis of Overall Survival of Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 6107.	1.7	6
674	Surgical Aspects of Intrahepatic Cholangiocarcinoma. Cancers, 2022, 14, 6265.	1.7	6
675	FGFR Inhibitors in Cholangiocarcinomaâ€"A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?. Cells, 2022, 11, 3929.	1.8	5
676	Suppressing of Srcâ€"Hic-5â€"JNKâ€"AKT Signaling Reduced GAPDH Expression for Preventing the Progression of HuCCT1 Cholangiocarcinoma. Pharmaceutics, 2022, 14, 2698.	2.0	1
678	Recent Advances in Intrahepatic Biliary Epithelial Heterogeneity. Seminars in Liver Disease, 2023, 43, 001-012.	1.8	1
679	Does Adjuvant Therapy Benefit Low-Risk Resectable Cholangiocarcinoma? An Evaluation of the NCCN Guidelines. Journal of Gastrointestinal Surgery, 2023, 27, 511-520.	0.9	2
680	Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. Journal of Vascular and Interventional Radiology, 2023, 34, 702-709.	0.2	6
681	Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments. Cancers, 2023, 15, 308.	1.7	2
682	Distinct cholangiocarcinoma cell migration in 2D monolayer and 3D spheroid culture based on galectin-3 expression and localization. Frontiers in Oncology, 0, 12, .	1.3	0
683	The impact of decreased expression of SVEP1 on abnormal neovascularization and poor prognosis in patients with intrahepatic cholangiocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
684	Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report and Literature Review of 890 Patients Affected by Uncommon Primary Liver Tumor Presentation. Journal of Clinical Medicine, 2023, 12, 423.	1.0	5
685	Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
686	Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping. Nature Communications, 2023, 14, .	5.8	6

#	Article	IF	Citations
687	Validation of the Prognostic Role for Surgical Treatment in Stage II Intrahepatic Cholangiocarcinoma: A SEER Population-Based Study. Journal of Clinical Medicine, 2023, 12, 675.	1.0	1
688	Pathology of Cholangiocarcinomas. Current Oncology, 2023, 30, 370-380.	0.9	7
689	Cost-Effectiveness Analysis of a New Second-Line Treatment RegimenÂfor Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FUÂChemotherapy. Pharmacoeconomics, 0, , .	1.7	1
690	Elevated ITGA2 expression promotes collagen type I-induced clonogenic growth of intrahepatic cholangiocarcinoma. Scientific Reports, 2022, 12, .	1.6	3
692	A combination therapy of bortezomib, CXCR4 inhibitor, and checkpoint inhibitor is effective in cholangiocarcinoma inÂvivo. IScience, 2023, 26, 106095.	1.9	2
693	Treatment Patterns and Survival in Locally Advanced or Metastatic Biliary Tract Cancer Using SEER Medicare Data. , 2023, , .		0
694	13â€‘cisâ€‘retinoic acid inhibits the selfâ€‘renewal, migration, invasion and adhesion of cholangiocarcinoma cells. International Journal of Molecular Medicine, 2023, 51, .	1.8	0
695	Curcumin-loaded nanocomplexes alleviate the progression of fluke-related cholangiocarcinoma in hamsters. Cancer Nanotechnology, 2023, 14, .	1.9	0
696	Contemporary advances in the endoscopic management of cholangiocarcinoma: a review of accomplished milestones and prospective opportunities. Expert Review of Gastroenterology and Hepatology, 2023, 17, 175-187.	1.4	0
698	Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review. Cells, 2023, 12, 370.	1.8	7
699	Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients. Clinical Epigenetics, 2023, 15, .	1.8	5
700	Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 985-999.	2.3	18
701	Whole-genome sequencing of 20 cholangiocarcinoma cases reveals unique profiles in patients with cirrhosis and primary sclerosing cholangitis. Journal of Gastrointestinal Oncology, 2023, 14, 379-389.	0.6	1
702	Racial Segregation Among Patients with Cholangiocarcinomaâ€”Impact on Diagnosis, Treatment, and Outcomes. Annals of Surgical Oncology, 2023, 30, 4238-4246.	0.7	7
703	CCL3 secreted by hepatocytes promotes the metastasis of intrahepatic cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (m6A) modification. Journal of Translational Medicine, 2023, 21, .	1.8	10
704	Artificial intelligence in endoscopic imaging for detection of malignant biliary strictures and cholangiocarcinoma: a systematic review. Annals of Gastroenterology, 2023, , .	0.4	3
705	The role of Kras and canonical Wnt pathways for tumorigenesis of extrahepatic biliary system. Oncotarget, 2023, 14, 54-56.	0.8	0
706	Durvalumab and biliary tract cancer: a breakthrough in the field of oncology. International Journal of Surgery Global Health, 2023, 6, e109-e109.	0.2	0

#	Article	IF	Citations
707	Identification and validation of volatile organic compounds in bile for differential diagnosis of perihilar cholangiocarcinoma. Clinica Chimica Acta, 2023, , 117235.	0.5	2
708	A preoperative scoring system to predict lymph node metastasis in intrahepatic cholangiocarcinoma. Hepatology International, 2023, 17, 942-953.	1.9	1
709	Mutational Impacts on the N and C Terminal Domains of the MUC5B Protein: A Transcriptomics and Structural Biology Study. ACS Omega, 2023, 8, 3726-3735.	1.6	3
710	Primary Liver Cancers: Connecting the Dots of Cellular Studies and Epidemiology with Metabolomics. International Journal of Molecular Sciences, 2023, 24, 2409.	1.8	1
711	Futibatinib forFGFR2-Rearranged Intrahepatic Cholangiocarcinoma. New England Journal of Medicine, 2023, 388, 228-239.	13.9	120
712	Combined Inhibition of Smoothened and the DNA Damage Checkpoint WEE1 Exerts Antitumor Activity in Cholangiocarcinoma. Molecular Cancer Therapeutics, 2023, 22, 343-356.	1.9	0
713	Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. Targeted Oncology, 2023, 18, 51-76.	1.7	2
714	Research Progress on Risk Factors of Cholangiocarcinoma. Advances in Clinical Medicine, 2023, 13, 4025-4031.	0.0	0
715	Metabolic reprogramming and its clinical implication for liver cancer. Hepatology, 2023, 78, 1602-1624.	3.6	10
716	Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology, 0, Publish Ahead of Print, .	3.6	3
717	Nivolumab in combination with dabrafenib and trametinib use in advanced cholangiocarcinoma with a BRAF V600E mutation and severe hepatic dysfunction: A case report and review of the literature. Journal of Case Reports and Images in Oncology, 2023, 9, 1-7.	0.0	0
718	Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis. Current Oncology, 2023, 30, 2613-2624.	0.9	2
719	MUG CCArly: A Novel Autologous 3D Cholangiocarcinoma Model Presents an Increased Angiogenic Potential. Cancers, 2023, 15, 1757.	1.7	0
720	Heterogeneity of Cholangiocarcinoma Immune Biology. Cells, 2023, 12, 846.	1.8	5
721	Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy. Oncologist, 2023, 28, 531-541.	1.9	2
723	The Japanese Clinical Practice Guidelines for intrahepatic cholangiocarcinoma: a comparison with Western guidelines. Hepatobiliary Surgery and Nutrition, 2023, 12, 244-247.	0.7	0
724	The interplay of signaling pathways with miRNAs in cholangiocarcinoma pathogenicity and targeted therapy. Pathology Research and Practice, 2023, 245, 154437.	1.0	40
725	Advanced endoscopy meets molecular diagnosis of cholangiocarcinoma. Journal of Hepatology, 2023, 78, 1063-1072.	1.8	3

#	Article	IF	Citations
726	Guanine nucleotide exchange factor T exerts the cancer-promoting function in cholangiocarcinoma by enhancing the Wnt-GSK-3Î²-Î²-catenin cascade via regulation of Rac1/Cdc42. Toxicology and Applied Pharmacology, 2023, 467, 116492.	1.3	0
727	Unraveling the heterogeneity of cholangiocarcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology. Biomedicine and Pharmacotherapy, 2023, 162, 114697.	2.5	1
729	Study of the association between a MICA gene polymorphism and cholangiocarcinoma in Egyptian patients. Clinical and Experimental Hepatology, 2022, 8, 293-299.	0.6	0
731	Immunology and immunotherapy of cholangiocarcinoma. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 349-365.	8.2	28
732	Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience. Cancers, 2023, 15, 733.	1.7	9
733	Fluorescence image-guided tumour surgery. , 2023, 1, 161-179.		27
734	Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study. Journal of Gastrointestinal Surgery, 2023, 27, 741-749.	0.9	3
735	Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 462-480.	8.2	9
736	ASO Author Reflections: Incorporating Circulating Tumor DNA in Perioperative Management of Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 0, , .	0.7	0
737	The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancerâ€"Challenges and opportunities. Frontiers in Molecular Biosciences, 0, 10, .	1.6	4
738	Preoperative subcategorization based on magnetic resonance imaging in intrahepatic cholangiocarcinoma. Cancer Imaging, 2023, 23, .	1.2	4
739	The risk factors of biliary fistula after radical resection of perihilar cholangiocarcinoma in elderly patients and its influence on prognosis: a retrospective cohort study. Journal of Gastrointestinal Oncology, 2023, 14, 390-404.	0.6	0
740	Loss of tumor suppressor menin expression in high grade cholangiocarcinomas. BMC Research Notes, 2023, 16, .	0.6	1
741	Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study. Scientific Reports, 2023, 13, .	1.6	1
742	Aberrant fucosylation sustains the NOTCH and EGFR/NF-ÎºB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma. Hepatology, 2023, 78, 1742-1754.	3.6	2
743	New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy. Cancers, 2023, 15, 1244.	1.7	13
744	Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases. Pharmacological Research, 2023, 189, 106706.	3.1	13
745	Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring. Annals of Surgical Oncology, 2023, 30, 3849-3863.	0.7	5

#	Article	IF	Citations
746	State of the Art: ctDNA in Upper Gastrointestinal Malignancies. Cancers, 2023, 15, 1379.	1.7	3
747	Bile metabolites as diagnostic biomarkers for perihilar cholangiocarcinoma. Scientific Reports, 2023, 13, .	1.6	2
748	Survival Benefit of Surgical Treatment for Elderly Patients with Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study in the SEER Database by Propensity Score Matching Analysis. Current Oncology, 2023, 30, 2642-2652.	0.9	0
749	Artificial intelligence CT radiomics to predict early recurrence of intrahepatic cholangiocarcinoma: a multicenter study. Hepatology International, 2023, 17, 1016-1027.	1.9	7
750	Knockdown of UBE2I inhibits tumorigenesis and enhances chemosensitivity of cholangiocarcinoma via modulating p27kip1 nuclear export. Molecular Carcinogenesis, 2023, 62, 700-715.	1.3	2
751	Omega-Class Glutathione Transferases Protect DNA from Oxidative Stress in Pathogenic Helminth Reproductive Cells. Antioxidants, 2023, 12, 560.	2.2	0
752	Spatiotemporal regulation of cholangiocarcinoma growth and dissemination by peritumoral myofibroblasts in a Vcam1-dependent manner. Oncogene, 2023, 42, 1196-1208.	2.6	1
753	The impact of hypoxia and oxidative stress on proteo-metabolomic alterations of 3D cholangiocarcinoma models. Scientific Reports, 2023, 13, .	1.6	1
754	Can repeated surgical resection offer a chance of cure for recurrent cholangiocarcinoma?. Langenbeck's Archives of Surgery, 2023, 408, .	0.8	3
755	A real-time interpretable artificial intelligence model for theÂcholangioscopic diagnosis of malignant biliary stricture (with videos). Gastrointestinal Endoscopy, 2023, 98, 199-210.e10.	0.5	7
756	Endobiliary radiofrequency ablation for unresectable malignant biliary strictures: Survival benefit perspective. Digestive Endoscopy, 2023, 35, 584-591.	1.3	2
757	Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment. Cancers, 2023, 15, 1454.	1.7	2
758	Current Perspectives in Liver Transplantation for Perihilar Cholangiocarcinoma. Current Oncology, 2023, 30, 2942-2953.	0.9	1
759	Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. Journal of Hepatology, 2023, 79, 93-108.	1.8	29
760	The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth. Cells, 2023, 12, 775.	1.8	1
761	Dense GM-CSFRÎ±-expressing immune infiltration is allied with longer survival of intrahepatic cholangiocarcinoma patients. PeerJ, 0, 11, e14883.	0.9	0
762	Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma. International Journal of Molecular Sciences, 2023, 24, 4748.	1.8	2
763	Panic at the Bile Duct. American Journal of Pathology, 2023, 193, 1440-1454.	1.9	3

#	Article	IF	Citations
764	Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma. JAMA Network Open, 2023, 6, e231476.	2.8	5
765	HSV: The scout and assault for digestive system tumors. Frontiers in Molecular Biosciences, 0, 10, .	1.6	0
766	Cholangiocarcinoma: Molecular Abnormalities and Cells of Origin. Technology in Cancer Research and Treatment, 2023, 22, 153303382211286.	0.8	3
767	Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma. Immunotherapy, 2023, 15, 487-502.	1.0	3
768	Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome. Cureus, 2023, , .	0.2	0
769	Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation. Oncology Research and Treatment, 2023, 46, 211-215.	0.8	3
770	Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy. Advanced Materials, 2023, 35, .	11.1	33
771	Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation. Journal of Medical Economics, 2023, 26, 454-462.	1.0	0
772	Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma. JHEP Reports, 2023, 5, 100723.	2.6	2
773	Surgery and hepatic artery infusion therapy for intrahepatic cholangiocarcinoma. Surgery, 2023, 174, 113-115.	1.0	1
775	NUF2 Drives Cholangiocarcinoma Progression and Migration via Inhibiting Autophagic Degradation of TFR1. International Journal of Biological Sciences, 2023, 19, 1336-1351.	2.6	2
776	Artificial intelligence in medical imaging for cholangiocarcinoma diagnosis: A systematic review with scientometric analysis. Journal of Gastroenterology and Hepatology (Australia), 2023, 38, 874-882.	1.4	5
777	Development and validation of machine learning models for predicting prognosis and guiding individualized postoperative chemotherapy: A real-world study of distal cholangiocarcinoma. Frontiers in Oncology, 0, 13, .	1.3	3
778	Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer, 2023, 12, 198-208.	4.2	2
779	The Cell Transformation Assay: A Historical Assessment of Current Knowledge of Applications in an Integrated Approach to Testing and Assessment for Non-Genotoxic Carcinogens. International Journal of Molecular Sciences, 2023, 24, 5659.	1.8	3
780	Adjuvant therapy for cholangiocarcinoma after surgery and prognosis factors for cholangiocarcinoma: A single-center retrospective cohort study. Frontiers in Oncology, 0, 13, .	1.3	1
782	Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma. Cancer Medicine, 2023, 12, 10156-10168.	1.3	5
783	Revival of associating liver partition and portal vein ligation for staged hepatectomy for perihilar cholangiocarcinoma: An international multicenter study with promising outcomes. Surgery, 2023, 173, 1398-1404.	1.0	3

#	Article	IF	Citations
784	3D-bioprinted cholangiocarcinoma-on-a-chip model for evaluating drug responses. Bio-Design and Manufacturing, 2023, 6, 373-389.	3.9	7
785	Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?. Immunotherapy, 2023, 15, 477-486.	1.0	1
786	TOPAZ-1: a new standard of care for advanced biliary tract cancers?. Immunotherapy, 0, , .	1.0	0
787	Serine/threonine kinase TBK1 promotes cholangiocarcinoma progression via direct regulation of Î²-catenin. Oncogene, 2023, 42, 1492-1507.	2.6	3
788	Galectin-9 in Gastroenterological Cancer. International Journal of Molecular Sciences, 2023, 24, 6174.	1.8	1
790	HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma. Biomarker Research, 2023, 11, .	2.8	16
791	Liver transplantation in the management of cholangiocarcinoma: Evolution and contemporary advances. World Journal of Gastroenterology, 0, 29, 1969-1981.	1.4	3
792	New challenges in cholangiocarcinoma candidates for elective surgery: harnessing the microbiome dysbiosis. Langenbeck's Archives of Surgery, 2023, 408, .	0.8	1
793	p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras. Oncotarget, 2023, 14, 276-279.	0.8	0
794	Precision Oncology Targets in Biliary Tract Cancer. Cancers, 2023, 15, 2105.	1.7	5
795	Malignant tumours of the liver. Surgery, 2023, , .	0.1	0
796	Role of the Gutâ€“Liver Axis in the Pathobiology of Cholangiopathies: Basic and Clinical Evidence. International Journal of Molecular Sciences, 2023, 24, 6660.	1.8	3
797	Role of sex in liver tumor occurrence and clinical outcomes: a comprehensive review. Hepatology, 0, Publish Ahead of Print, .	3.6	2
798	Comparison between suprapapillary and transpapillary uncovered self-expandable metallic stent placement for perihilar cholangiocarcinoma. Journal of Vascular and Interventional Radiology, 2023, , .	0.2	0
799	Tumor-Infiltrating B Lymphocytes: Promising Immunotherapeutic Targets for Primary Liver Cancer Treatment. Cancers, 2023, 15, 2182.	1.7	2
800	Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. Journal of the National Cancer Institute, 2023, 115, 870-880.	3.0	4
801	Impact of Aberrant Î²-Catenin Pathway on Cholangiocarcinoma Heterogeneity. Cells, 2023, 12, 1141.	1.8	3
802	Morphometric analysis of tumor microvessels for detection of hepatocellular carcinoma using contrast-free ultrasound imaging: A feasibility study. Frontiers in Oncology, 0, 13, .	1.3	3

#	Article	IF	Citations
803	Metabolicâ€“related gene signatures for survival prediction and immune cell subtypes associated with prognosis in intrahepatic cholangiocarcinoma. Cancer Genetics, 2023, 274-275, 84-93.	0.2	0
804	Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment. Current Oncology, 2023, 30, 4185-4196.	0.9	2
805	Readiness for hospital discharge post-initial invasive percutaneous transhepatic biliary drainage: A mixed-methods study. Heliyon, 2023, 9, e15341.	1.4	2
806	Plumbagin Suppresses Growth, Induces Apoptosis, and Inhibits Migration in Cholangiocarcinoma via Reactive Oxygen Species Generation and Mitochondrial Function. Pharmacognosy Magazine, 0, , 097312962311582.	0.3	0
807	Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features. Expert Review of Molecular Diagnostics, 2023, 23, 445-456.	1.5	1
808	EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. Journal of Hepatology, 2023, 79, 181-208.	1.8	33
809	Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues. Cancers, 2023, 15, 2376.	1.7	1
810	Identification of a Novel NRG1 Fusion with Targeted Therapeutic Implications in Locally Advanced Pediatric Cholangiocarcinoma: A Case Report. Case Reports in Oncology, 0, , 255-261.	0.3	0
811	Diagnosis and Treatment of Perihilar Cholangiocarcinoma: A National Survey from the Korean Pancreatobiliary Association. Gut and Liver, 2024, 18, 174-183.	1.4	0
832	Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma. Frontiers in Immunology, 0, 14, .	2.2	2
920	Cancer Vaccines. , 2023, , 191-210.e9.		0
923	IFC in Primary and Metastatic Liver Tumours. , 2023, , 283-291.		0
930	Friend or foe? The elusive role of hepatic stellate cells in liver cancer. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 647-661.	8.2	11
936	Molecular Imaging of Hepatobiliary Cancers. , 0, , .		0
955	The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility. Recent Results in Cancer Research, 2023, , 53-90.	1.8	0
969	Systemic Treatment for Cholangiocarcinoma. Recent Results in Cancer Research, 2023, , 223-244.	1.8	1
998	Editorial: Biomarkers and immunotherapy of hepatic-biliary-pancreatic cancers. Frontiers in Oncology, 0, 13, .	1.3	0
1035	Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma. Frontiers in Immunology, 0, 14, .	2.2	0

#	Article	IF	Citations
1098	Experimental Model of Biliary Tract Cancers: Subcutaneous Xenograft of Human Cell Lines in Immunodeficient Nude Mice. Methods in Molecular Biology, 2024, , 87-98.	0.4	0
1099	Oncogene-Driven Induction of Orthotopic Cholangiocarcinoma in Mice. Methods in Molecular Biology, 2024, , 99-108.	0.4	0
1128	Percutaneous Radiofrequency Ablation in the Treatment of Primary Liver Cancers. , 2024, , 1-14.		0
1154	Editorial: Role of imaging in biliary tract cancer: diagnosis, staging, response prediction and image-guided therapeutics. Frontiers in Oncology, 0, 14, .	1.3	0